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Thought is believed to be created by communication between neurons. Neurons 
communicate over cell-cell junctions called synapses. The number and function of 
neuronal synapses are not fixed but can be altered by a number of different mechanisms, 
so-called synaptic plasticity.  For example, experience of the outer world can strengthen 
or weaken particular sets of synapses, thereby changing how the brain processes 
information and directs behavior. The work for this dissertation focused on the protein O-
GlcNAc transferase (OGT). The activity of OGT is controlled by the metabolic status of 
the cell and the body. It was known that OGT is expressed in neurons. We hypothesized 
that if OGT would regulate synaptic plasticity, then investigations into the function of 
OGT may offer an opportunity to better understand how stimuli from the surrounding 
environment may influence thinking. Combining biological chemistry and animal 
behavior, we discovered that OGT maintains normal body weight in αCaMKII neurons of 
the paraventricular nucleus (PVN) of the hypothalamus. It turns out that these neurons 
participate in a negative feedback loop that becomes activated upon food intake to turn 
off further intake. By sensing the caloric content of what is being ingested, OGT sets the 
threshold of this loop by mediating how many excitatory synapses αCaMKII PVN 
neurons express. Further studies showed that OGT is enriched in the postsynaptic density 
of excitatory synapses and regulates their maturity in a range of different types of 
neurons. The argument of this dissertation holds that nutrient-dependent regulation of 
synaptic plasticity by OGT is an attractive target for future inquiry of the connection 
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1.1 Abstract 
O-GlcNAc is the attachment of -N-acetylglucosamine to the hydroxyl group of serine 
and threonine in nuclear and cytoplasmic proteins (1). It is generally not further elongated 
but exists as a monosaccharide that can be rapidly added or removed (2). Thousands of 
proteins involved in gene transcription, protein translation and degradation as well as the 
regulation of signal transduction contain O-GlcNAc (3, 4). Brain is one of the tissues 
where O-GlcNAc is the most highly expressed and deletion of neuronal O-GlcNAc leads 
to death early in development (5, 6). O-GlcNAc is also important for normal adult brain 
function, where dynamic processes like learning and memory at least in part depend on 
the modification of specific proteins by O-GlcNAc (7, 8). Conversely, too much or too 
little O-GlcNAc on other proteins participates in neurodegenerative processes underlying 
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diseases such as Alzheimer's and Parkinson's (9-13). In this chapter, I describe the 
expression and regulation of O-GlcNAc in the nervous system. 
1.2 O-GlcNAc is a ubiquitous monosaccharide that cycles onto and off 
serine and threonine  
1.2.1 O-GlcNAc is not elongated to yield complex oligosaccharides  
O-GlcNAc is the covalent modification of nuclear and cytoplasmic proteins by -N-
acetylglucosamine (1). O-GlcNAc is formed as a derivative of glucose through the 
hexosamine biosynthesis pathway (HBP). In the HBP, the oxygen on the second carbon 
of fructose-6-phosphate is exchanged for nitrogen forming GlcN-6-P, prior to acetylation 
of the nitrogen to yield GlcNAc-6-P. This is then coupled to the high-energy molecule 
uridine diphosphate (UDP), UDP-GlcNAc. Upon modification of proteins by O-GlcNAc, 
the GlcNAc is cleaved from the UDP and attached in -position to the hydroxyl group of 
serine or threonine (O--GlcNAc, O-GlcNAc). The reaction is catalyzed by the O-
GlcNAc transferase, OGT. The removal of GlcNAc is catalyzed by the O-GlcNAc 
hydrolase, O-GlcNAcase (OGA).  
 Unlike 'classical' O- and N-linked protein glycosylation the GlcNAc is generally 
not elongated but exists as a monosaccharide. In fact, when O-GlcNAc is artificially 
capped by galactose, its biological function is lost (14). Although O-GlcNAc is smaller 
than complex oligosaccharides, it is still much larger than many other protein 
modifications, such as protein methylation or protein phosphorylation (2). 
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1.2.2 O-GlcNAc is mostly expressed on the inside of cells in multicellular 
organisms 
O-GlcNAc is a highly conserved posttranslational modification. It has been found in 
evolutionarily distinct clades like plantae, fungi and animalia (5, 15). In multicellular 
organisms, all types of cells investigated so far contain O-GlcNAc (2). O-GlcNAc has 
also been identified in some unicellular organisms, e.g. giardia - the oldest eukaryote, and 
inside several types of virus (16-18). Nonetheless, most studies on unicellular organisms 
fail to report the presence of -O-GlcNAc. Protozoans modify proteins by O-linked 
GlcNAc but primarily on extracellular proteins and in -linkage rather than in -linkage. 
Yeasts appear to lack O-GlcNAc entirely, but recent studies suggest that they use O-
mannose cycling for similar functions carried out by O-GlcNAc in higher organisms (19). 
Bacteria are also largely devoid of cytoplasmic O-GlcNAc even though some bacterial 
proteins have been shown to carry O-linked GlcNAc (20, 21). Interestingly, the 
bacterium Clostridium novyi exploits O-GlcNAc by encoding an O-GlcNAc transferase 
that modifies small G-proteins in the infected cell (2, 22, 23).  
 O-GlcNAc is expressed almost exclusively on the inside of cells (1). Until the 
discovery of O-GlcNAc protein glycosylation was known to occur only on proteins 
exposed to the extracellular matrix, or in cellular organelles topographically similar to the 
outside of the cell such as the endoplasmic reticulum (ER) and the Golgi apparatus. In 
contrast, nearly all proteins that contain O-GlcNAc are expressed in the cytosolic or 
nuclear fraction of the cell. Proteins anchored to the cell membrane are modified with O-
GlcNAc but usually only on parts stretching into the cytosol. This comes as no surprise as 
the O-GlcNAc transferase, OGT, is mainly nucleocytoplasmic rather than present in the 
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Golgi or ER as other glycosyltransferases (there are at least two O-GlcNAc transferases 
with their active sites in the lumen of the ER, called, eOGTs, but these enzymes are 
distinct from the enzyme regulating nucleocytoplasmic O-GlcNAc. O-GlcNAc has been 
detected on extracellular domains of a handfull of proteins, e.g. notch) (see section 2.2; 
(4). Also the hexosaminidase removing O-GlcNAc, OGA, is cytosolic and active at 
neutral pH (see section 2.3). By comparison, cellular glycosidases breaking down 
glycoconjugates retrieved from the cell surface are primarily found in the lysosome and 
prefer an acidic milieu. 
Importantly, the concentration of O-GlcNAc is not uniform across the cell. Some parts, 
like the nuclear membrane, are heavily modified whereas other parts, like the 
mitochondria, contain O-GlcNAc but to a lesser degree. All major organelles and other 
cytosolic substructures, e.g. the proteasome and ribosome, express O-GlcNAc (24-26). 
The precise level varies over time and is finely tuned to meet the conditions of the cell 
(see sections 1.3, 3 and 4).   
1.2.3 O-GlcNAc can be dynamically attached and removed 
Whether or not a protein is modified by O-GlcNAc varies substantially over time. On 
many proteins, including the heat-shock protein B-crystallin, the O-GlcNAc half-life is 
much shorter than the half-life of the peptide backbone (27). In fact, studies using 
selective inhibitors of the enzyme that removes O-GlcNAc from proteins, OGA, show 
that cycling rates are often on the order of minutes, making O-GlcNAc more akin to 
protein phosphorylation than 'classical' protein glycosylation. 'Classical' N- and O-linked 
glycosylation of proteins, glycosylation of proteins exposed to the extracellular matrix or 
within the secretory pathway, is, largely, stable once the mature glycan has been attached. 
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There are examples of proteins, e.g. the nucleoporins that form pores through the nuclear 
membrane, where the O-GlcNAc does not appear to turnover faster than the protein itself 
(28, 29).  
 It has been proposed that O-GlcNAc cycling works like a light switch with only 
two modes of operation - either 'on' or 'off'. One argument in favor of this idea is the fact 
that there are only two enzymes that add and remove O-GlcNAc from proteins, OGT and 
OGA, respectively (see section 2). Indeed, in some situations cells react by either 
elevating or suppressing global O-GlcNAc levels. For example, abundant nutrient supply 
leads to a general increase in O-GlcNAc and scant supply to a general decrease (see 
sections 2.2 and 4.3). Likewise, cellular stress is associated with raised O-GlcNAc 
throughout the cell (30). All the same, early studies showed that activation of 
lymphocytes causes O-GlcNAc levels in the cytosol to go up while they go down in the 
nucleus (31). A recently developed FRET (fluorescence resonance energy transfer) 
reporter that measures OGT activity in real-time demonstrated further that during serum 
stimulation of transformed cell lines, OGT was activated many fold in some parts of the 
cytosol whereas in nearby areas OGT activity remained at baseline (32). Work on the 
regulation of signal transduction by O-GlcNAc describes the same picture; upon 
stimulation, in a single pathway there can be proteins that become better substrates for 
OGT but also proteins that become worse substrates for OGT (33). Thus, despite there 
being only two enzymes that add and remove O-GlcNAc, changes in O-GlcNAc can 
occur 'locally' within the cell. For example, by forming dynamic multi-partner complexes 
OGT and OGA can be directed towards select targets among a broader range of available 
substrates (see sections 2.2-3; (34-36)). 
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 The spatiotemporal regulation of O-GlcNAc cycling is complex and occurs on 
many levels. While nutrients and stress can cause global changes in O-GlcNAc, binding 
partners to OGT and OGA tune O-GlcNAc occupancy locally. Below I will discuss in 
detail how O-GlcNAc cycling is controlled in the nervous system and how the dynamic 
modification of proteins by O-GlcNAc helps the brain to develop and respond to 
challenges in the environment.   
1.3 O-GlcNAc is added to proteins by OGT and removed by OGA 
1.3.1 Only two enzymes regulate the cycling of O-GlcNAc 
O-GlcNAc exists as a monosaccharide on nuclear and cytoplasmic proteins and can cycle 
rapidly and repeatedly over the lifetime of the polypeptide chain (see section 1). In a 
single cell, including neurons, thousands of proteins carry O-GlcNAc ((3); see section 
3.2). Changes in O-GlcNAc can happen globally throughout the cell but also locally on 
individual proteins or sites within a protein (see section 1.3). In mammals, there are only 
two enzymes that add and remove O-GlcNAc. The O-GlcNAc transferase (OGT) adds O-
GlcNAc to proteins (5, 37). The O-GlcNAc glycosidase, O-GlcNAcase (OGA), removes 
O-GlcNAc from proteins (38, 39). As we will see in section 3, loss or deregulation of O-
GlcNAc cycling leads to severe developmental brain defects, impaired brain function in 
the adult and risk for many neurodegenerative disorders, e.g. Alzheimer's disease. In this 
section we will discuss how OGT and OGA are both promiscuous in order to accept a 
broad range of targets while at the same time specific to ensure that O-GlcNAc cycles on 
the correct site at the correct time and place.  
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1.3.2 O-GlcNAc transferase; a highly conserved glycosyltransferase present in 
the nucleus & cytosol 
In mammals, O-GlcNAc transferase (OGT) is encoded by a single gene. The gene is 
highly conserved and lies close to the centromeric region of the X chromosome (Xq13) 
(5, 40, 41). It spans about 45 kilobase pairs (kb) and its locus is linked to Parkinsonian 
dystonia, a neurodegenerative movement disorder (41, 42). In most organs there are five 
major OGT transcripts ranging from 4.2kb to 9.5kb. The transcripts undergo alternative 
splicing. In brain the larger 9.5kb and 6.4kb transcripts, which include exons located 5' of 
the internal promoter, dominate (41, 43). Most studies so far argue that the total 
expression of OGT is stable during most conditions. However, little is known about the 
regulation of the OGT gene and at least in neuroblastoma cells OGT mRNA increases 
after depriving the cells of glucose (35).  
 The protein encoded by OGT contains two major domains. The N-terminal half is 
comprised of several tetratricopeptide (TPR) repeats and the C-terminal half binds UDP-
GlcNAc and harbors the glycosyltransferase activity. The TPR repeats form a flexible 
superhelix that can accommodate many protein-protein interactions (5, 44-46). The C-
terminus exhibits a more compact structure and resembles members of the GT-B 
superfamily of glycosyltransferases (Gtfs) but adopts some unique folds as well (47). 
While most OGT-interacting proteins are believed to bind the TPR repeats the C-
terminus includes regions that are necessary and sufficient for some interactions, e.g. to 
the mitogen-activated kinase (MAPK) p38 in neurons (35). The C-terminus also mediates 
translocation to the cell membrane upon insulin stimulation, probably via a cluster of 
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lysines that pairs electrostatically with negatively charged phosphatylinositol (3,4,5)-
triphosphate (PIP3) (48). 
 Catalysis occurs by an ordered sequential mechanism where OGT binds first 
UDP-GlcNAc and then the substrate. A hydroxyl group on the incoming substrate 
performs a direct nucleophilic attack on the anomeric carbon on GlcNAc, thereby 
inverting the glycosidic bond from UDP--GlcNAc to (serine/threonine-) O--GlcNAc. 
There is a general base and a general acid that catalyze the nucleophilic attack by 
activating the hydroxyl group (47, 49). In vitro experiments have shown that if the TPR 
domain is removed from OGT, the C-terminus alone can modify peptides with O-
GlcNAc. In contrast, for protein substrates to be modified, the TPR domain is required  
(44, 45). It has been hypothesized based on computer simulations that the TPRs induce a 
conformational change in the substrate that enables the O-GlcNAc site to dock at the 
catalytic groove. Most likely, OGT goes through a conformational change as well; the 
TPR helix pivots around the intervening region between the TPRs and the C-terminus 
exposing the entrance to the groove (3, 47).  
 Three major isoforms of OGT have been described (43). All share the same 
catalytic domain but differ in their N-terminus. Nucleocytoplasmic OGT (ncOGT) is the 
full-length variant and includes 11-12 TPRs, depending on the species. Mitochondrial 
OGT (mOGT) starts with a mitochondrial targeting sequence, followed by a membrane-
spanning region and continues with the last 9 TPRs found in ncOGT. The third, and 
shortest, isoform is soluble OGT (sOGT). It contains only 3 TPRs. According to most 
studies, only ncOGT is present in total brain lysate (5, 50). However, sOGT may become 
upregulated in older animals and little is known about whether mOGT or sOGT is present 
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in specific regions of the brain or in specific subcellular compartments (51). Apart from 
mOGT, which is anchored to the inner membrane of the mitochondria, almost all OGT 
activity is found in the nucleocytoplasm or as a non-integral membrane protein associated 
with the cytosolic face of cell membranes (37, 43). 
 In vivo, OGT oligomerizes into a dimer or trimer (5, 50). OGT was first purified 
from rat liver and described as a heterotrimer consisting of two ncOGT and one 78kDa 
unit. The 78kDa unit is enriched in certain tissues and may correspond to sOGT, but may 
also be a proteolytic fragment of ncOGT (5, 52). The major form of OGT expressed in 
brain is more likely a homodimer of ncOGT (50). Dimerization occurs over an 
evolutionary conserved hydrophobic region in the TPR domain (TPR 6). Dimerization is 
stable even in very high salt concentrations and probably not subject to posttranslational 
regulation (45, 46).  
 OGT is exquisitely regulated adding O-GlcNAc only to particular sites at any 
given time and place. In vitro, OGT exhibits sequence specificity. If purified OGT is 
mixed with UDP-GlcNAc and a peptide that contains several possible O-GlcNAc sites, 
often only one or a few sites become significantly modified. Likewise, substrate peptides 
derived from different proteins are often modified with different efficiency (45). Also 
UDP-GlcNAc levels influence peptide substrate specificity (45, 53). Nevertheless, there 
is no absolute substrate consensus sequence for OGT. Indeed, the catalytic site of OGT 
interacts primarily with the peptide backbone of the substrate and not particular side 
chains (47). In vivo, O-GlcNAc sites concentrate on disordered regions of proteins and 
close to proline and valine, so called PVS motifs (2-4). Presumably, the reason is that 
such regions can be made to fit OGT's catalytic groove more easily.  
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 Primary sequence plays a role in determining the major O-GlcNAc sites on a 
given protein. However, in cells, whether a particular protein will be modified depends 
also on OGT-binding proteins. OGT operates as a holoenzyme, where its interacting 
proteins direct OGT to its substrates (34-36, 50, 54, 55). For example, in neurons, 
neurofilaments become O-GlcNAcylated only after activated p38 binds OGT (54). OGT-
interacting proteins can enhance OGT activity towards peptide substrates as well (50). 
Moreover, OGT is multiply phosphorylated and it modifies itself with O-GlcNAc (5, 34, 
56). Phosphorylation of OGT can both activate OGT, e.g. via calcium/calmodulin-
dependent kinase IV (CaMKIV) during neuronal depolarization, and alter OGT's 
substrate specificity (34, 56, 57). OGT is strongly inhibited by free UDP but, unlike most 
other glycosyltransferases that utilize a UDP-bound sugar as donor, OGT does not 
require divalent cations (37). 
 OGT has emerged as a key cellular nutrient sensor. The donor for O-GlcNAc, 
UDP-GlcNAc, is produced by the hexosamine biosynthesis pathway, the HBP (see 
section 1.1). UDP-GlcNAc is an abundant high-energy small molecule and ranges in 
concentrations within cells from 0.1 to 1mM. Almost all metabolic pathways feed into 
the HBP and contribute to the production of UDP-GlcNAc, including fatty acids, nitrogen 
and 2-5% of all cellular glucose. A rich energy supply elevates UDP-GlcNAc, and, 
subsequently, protein O-GlcNAcylation whereas a scarce supply is associated with 
reduced levels of both UDP-GlcNAc and O-GlcNAc (2, 23). Also in the brain fasting has 
been shown to decrease O-GlcNAc generally, a change reversed upon re-feeding (10, 
58). Interestingly, depending on the substrate, the Km for UDP-GlcNAc can vary more 
than 20-fold but most become better substrates in the presence of higher concentrations 
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of UDP-GlcNAc (45, 53). Therefore, although metabolic flux is associated with global 
changes in O-GlcNAc, some proteins are more sensitive to nutrient supply than others. In 
section 4.3 we will discuss how OGT as a nutrient sensor is involved in the pathology 
behind neurodegenerative disease.  
1.3.3 O-GlcNAcase; a cytosolic O--GlcNAc hydrolase with neutral pH optima 
In accord with the O-GlcNAc transferase, the enzyme that removes O-GlcNAc from 
proteins, O-GlcNAcase (OGA), is expressed from a single gene. The gene was first 
cloned as an antigen associated with meningioma and it is localized to the long arm of 
chromosome 10 (10q24), a locus tightly linked to late-onset Alzheimer's disease (59, 
60)). In addition, alternatively spliced OGA transcripts have been associated with 
sporadic cases of Alzheimer's disease (61).  
 OGA hydrolyses GlcNAc from proteins using substrate-assisted catalysis. Two 
aspartates activate the acetamido group on GlcNAc's second carbon to perform a 
nucleophilic attach on its anomeric carbon. This results in the displacement of GlcNAc 
from the protein (62). Contrary to most hexosaminidases, OGA has neutral pH optima 
and is not inhibited by GalNAc. Nor does it remove GalNAc from proteins but is specific 
for -linked O-GlcNAc (38). OGA is also genetically and immunogenically distinct from 
other glycosidases (39).  
 OGA has been identified in all tissues so far investigated. It is expressed in the 
nucleus and cytoplasm of cells and the highest expression is found in brain (39). OGA is 
highly conserved but contains a middle, intrinsically unfolded region that exhibits more 
variability (39, 59, 63). Like OGT, OGA consists of two major domains. The glycosidase 
domain is C-terminal. The N-terminus contains a histone acetyl transferase (HAT) 
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domain. While the HAT domain was reported to be functionally active (64, 65), other 
groups have not been able to repeat this finding (63). Caspase 3 cleaves OGA between 
the glycosidase domain and the HAT domain during apoptosis without any loss of O-
GlcNAcase activity (63).  
 Very little is known about the regulation of OGA. It is believed that OGA forms 
multi-partner complexes that direct OGA to its substrates, much like how OGT is 
regulated ((2); see above). Recently, highly specific pharmacological inhibitors of OGA 
have been developed (11, 66). In section 4 we will learn more about the way in which 
OGA is important for the brain's ability to learn and form memories and serves as a drug 
target for neurodegenerative disorders.  
1.4 O-GlcNAc is highly expressed in the nervous system 
1.4.1 O-GlcNAc is found throughout the brain 
Brain is one of the organs where O-GlcNAc is the most abundant. OGT and OGA are 
expressed in comparatively high levels in the brain (5, 39, 67). Both enzymes are present 
across brain regions, including cortex, the cerebellum and subcortical nuclei such as the 
amygdala (8, 51). Within neurons, O-GlcNAc has been identified in all subcellular 
structures investigated, albeit to differing degrees. Biochemical fractionation was used to 
show that O-GlcNAc transferase activity was present in synapses (68). Immunoelectron 
microscopy indicated that OGT and O-GlcNAc were present in both the post- and pre-
synapse. In the presynapse, OGT is concentrated on synaptic vesicles storing 
neurotransmitter (69). Most research on O-GlcNAc in the brain has focused on O-
GlcNAc's role in neurons of the central nervous system. Less is known about its 
expression in neurons of the peripheral nervous system or in glia. 
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1.4.2 Thousands of neuronal proteins are modified by O-GlcNAc 
One difficulty in studying the role of O-GlcNAc for brain function is its vast abundance. 
Technical breakthroughs have allowed identification of O-GlcNAc sites en masse by 
coupling selective enrichment of O-GlcNAc modified proteins with electron capture 
dissociation (ECD) or electron transfer dissociation (ETD) mass spectrometry (types of 
mass spectrometry that can fragment peptides without losing the GlcNAc) (3, 70). 
According to some estimates, about 40% of all neuronal proteins are modified by O-
GlcNAc (3). Some proteins, like bassoon, which is important for neurotransmitter 
release, have more than a dozen O-GlcNAc sites. On other proteins, e.g. CaMKII, only a 
single site has been detected (3). As discussed in section 2.2 O-GlcNAc sites concentrate 
on structurally disordered regions of proteins and there is some preference for a sequence 
context rich in proline and valine. For any particular site, O-GlcNAc is usually present in 
substochiometric levels (23). The absolute occupancy is dynamic and depends on the 
activity of the neuron, possibly due to CaMK-dependent stimulation of OGT (56, 71, 72).  
 Proteins modified by O-GlcNAc belong to all functional classes. Many O-
GlcNAc proteins are shared across cell types and underlie constitutive cellular functions 
such as transcription, translation and protein degradation. Nevertheless, the role played 
by O-GlcNAc on these factors is often neuron-specific. For example, in neurons, the 
common transcription factor cyclic AMP-response element binding protein (CREB) is 
modified by O-GlcNAc on serine 40 upon cell depolarization. Once modified, CREB is 
prevented from binding to its co-activator CRTC (CREB-regulated transcription 
coactivator). This inhibits CREB and leads to an inactivation of several transcription 
pathways involved in synaptic plasticity (see section 4.2; (8)). Other O-GlcNAc proteins 
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are particular to neurons, including certain scaffolding proteins, signaling proteins and 
cytoskeletal proteins. Many of these are proteins found in the synapse. One interesting 
case is CaMKII. CaMKII is modified by O-GlcNAc in a small region known to 
contain one phosphorylation site that can activate the enzyme and another 
phosphorylation site that deactivates it (3). The regulation of CaMKII activity is crucial 
for synaptic events that underlie learning and memory (73). Therefore, elucidation of how 
O-GlcNAc may fine tune CaMKII activity is important not only to our understanding of 
synapse biology but also higher-order brain function. Moreover, in the synapse, there is a 
significant overrepresentation of kinases, the enzymes that add O-phosphate to proteins, 
among the proteins that are modified by O-GlcNAc (3). 
 Several proteins that contribute to the development of neurocognitive disease 
carry O-GlcNAc. The transcription factor methyl CpG binding protein 2 (MeCP2) 
coordinates activity-dependent gene transcription and is modified by O-GlcNAc. Loss of 
MeCP2 causes Rett syndrome, a developmental disorder classically associated with 
repetitive and stereotypical hand movements and mental retardation. It has been shown 
that only the MeCP2 molecules that do not carry O-GlcNAc were activated in response to 
neuronal depolarization (8, 70). Seemingly on MeCP2, O-GlcNAc serves as a checkpoint 
for turning on or off activity-dependent gene transcription. Other O-GlcNAc proteins that 
are intimately involved in neurocognitive disease include tau (Alzheimer's disease) and 
-synuclein (Parkinson's disease) (9, 70).  
1.4.3 O-GlcNAc regulates diverse cellular processes 
Proteins modified by O-GlcNAc regulate diverse cellular processes such as gene 
transcription, protein translation and degradation and signal transduction. The function of 
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the O-GlcNAc modification depends on the specific protein that is modified as well as 
the site on that protein that is modified (2, 74). Here we will briefly discuss different 
mechanisms by which O-GlcNAc underlies normal cell function.  
 Gene transcription 
RNA polymerase II. O-GlcNAc may directly affect basal transcription by inactivating 
RNA polymerase II. RNA polymerase II in the so-called pre-initiation complex is heavily 
modified by O-GlcNAc in its carboxyl terminal domain (CTD). However, the RNA 
polymerase II in the so-called elongation complex is devoid of O-GlcNAc. Instead, upon 
transcription initiation the CTD of RNA polymerase II becomes phosphorylated. It has 
been suggested that the loss of O-GlcNAc is required before it can be phosphorylated and 
thereby activated (75-77).  
 Histones. Histones are modified by multiple posttranslational modifications, 
including O-GlcNAc (78). The combination of these modifications are hypothesized to 
form a 'code' that either facilitates or prevents the access of transcription factors to DNA. 
The O-GlcNAc on serine 112 enhances the (mono-) ubiquitination of histone 2B thereby 
activating gene transcription (79).  
 Transcription factors. O-GlcNAc takes advantage of several different 
mechanisms to regulate the activity of transcription factors toward gene transcription 
(80). O-GlcNAc activates NeuroD by promoting its shuttling from the cytosol to the 
nucleus and protects p53 by saving it from ubiquitin-mediated degradation (81). O-
GlcNAc on serine 228 on Oct4 does not affect its general activity but influences its 
promoter specificity (82). 
 Protein translation 
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O-GlcNAc plays several distinct roles during the translation of messenger RNA to 
polypeptide chains. OGT and OGA bind very tightly to the ribosome and overexpression 
of OGT was shown to facilitate ribosome assembly. Several ribosomal proteins are 
modified by O-GlcNAc, including the mammalian target of rapamycin (mTOR) pathway 
protein S6 (26). Also associated translational factors are modified by O-GlcNAc. The 
eukaryotic initiation factor 2 (eIF2) initiates translation by forming a complex with p67. 
It has been suggested that the O-GlcNAc on p67 is required for p67's ability to protect 
eIF2 from phosphorylation and thereby inactivation (83, 84). 
 Protein and vesicle trafficking 
The subcellular distribution of multiple proteins has been shown to depend on O-GlcNAc 
(85, 86). For instance, E-cadherin is a cell junction protein that, among other things, is 
important for inhibitory synapse formation (87). If the O-GlcNAc on E-cadherin's 
cytosolic tail is not removed, E-cadherin becomes trapped in the endoplasmatic reticulum 
(ER) and cannot be transported further to the Golgi apparatus (86). O-GlcNAc may also 
play a role in the transport of microvesicles within cells, e.g. vesicles that mediate the 
release of neurotransmitter. There is no direct evidence showing that O-GlcNAc regulates 
microvesicle trafficking per se. However, proteins such as adaptor protein complex 2 
(AP-2) that mediates clathrin-dependent endocytosis and N-ethylmaleimide-sensitive 
fusion protein (NSF), which is an ATPase involved in vesicle fusion, are modified by O-
GlcNAc (88).  
 Protein degradation 
O-GlcNAc is intimately involved in the control of protein degradation. O-GlcNAc sites 
often fall in regions with high PEST-scores (the Pro-Glu-Ser-Thr sequence is associated 
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with rapid degradation of proteins) and an increase in global O-GlcNAc leads to an 
increased ubiquitination of proteins whereas a decrease in global O-GlcNAc decreases 
protein ubiquitination (23, 89). In addition, O-GlcNAc can directly inhibit the proteasome 
by modifying the 26S and 19S proteasomes (25).  
 Signaling and the crosstalk between O-GlcNAc and O-phosphate 
An emerging theme in the regulation of signal transduction pathways is the crosstalk 
between O-GlcNAc and O-phosphate. Many O-phosphorylated proteins are also O-
GlcNAc proteins (3). O-GlcNAc and O-phosphate can directly and reciprocally inhibit 
each other by sharing the same site, as in the case of threonine 58 in the trans-activation 
domain of the transcription factor c-myc (90, 91). On other proteins the crosstalk is 
indirect and can be both negative and positive. Removal of O-GlcNAc from threonine 
57/serine 58 on CaMKIV, for example, prevents the phosphorylation of threonine 200, 
the main activation site on CaMKIV. At the same time, loss of O-GlcNAc on serine 189 
facilitates threonine 200 phosphorylation (92). In fact, on a global level, the occupancy of 
most dynamic phosphorylation sites is affected by acute inhibition of O-GlcNAc cycling 
(93). As a group, kinases, the enzymes that add O-phosphate to proteins, are more often 
modified by O-GlcNAc than other kinds of proteins (3, 94). Furthermore, as discussed in 
section 2.2, phosphorylation of OGT can activate OGT and influence its substrate 
specificity.  
1.5 O-GlcNAc is essential for brain function 
In sections 1-3 we have learned that O-GlcNAc dynamically modifies a vast array of 
neuronal proteins involved in many cellular processes, such as gene transcription and 
signal transduction. In the following section I will discuss how the regulation of neuronal 
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function by O-GlcNAc underlies normal brain function and contributes to neurocognitive 
disease.  
1.5.1 Early and late brain development depend upon O-GlcNAc cycling 
In vertebrates, O-GlcNAc is essential for normal development. In many different cell 
types, it has been shown that perturbations of O-GlcNAc cycling interrupt the cell cycle 
by preventing cytokinesis (70, 95, 96). In the embryo, this leads to failure of stem cell 
proliferation and subsequent death at the single cell stage (40). Studies taking advantage 
of partial depression of OGT expression, where cell proliferation is preserved, indicated 
that renewal of stem cell pluripotency and stem cell differentiation depend upon O-
GlcNAc. In fact, two members of the core pluripotency network in embryonic stem cells, 
Oct4 and Sox2, are modified by O-GlcNAc. Loss of O-GlcNAc on threonine 228 of Oct4 
alters its promoter specificity disrupting transcription of dozens of genes, including some 
that are involved in neuronal differentiation (e.g. Nanog) (82, 97).  
 Later in development, O-GlcNAc plays a role in brain morphogenesis and 
patterning. Loss of OGT decreases brain size, while overexpression of OGT blurs the 
organization and distinction of hind-, mid- and forebrain regions in zebra fish (15). 
Likewise, when OGT was deleted from neurons specifically by crossing floxed OGT 
mice with mice expressing Cre recombinase under the synapsin I promoter, viability until 
term was reduced. The pups that survived failed to develop any locomotor activity and 
died within ten days (6). In postmitotic neurons, the O-GlcNAc glycosylation of CREB 
underlies both axonal and dendritic growth and may, at least partly, explain the impaired 
development of brain function (8). O-GlcNAc is also known to affect axonal branching 
(98). 
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1.5.2 O-GlcNAc is associated with learning and memory 
Learning and memory are fundamental properties of the brain. Over the past decades it 
has been shown that the brain is a highly malleable organ that dynamically responds to 
challenges in the environment. It is believed that memories are encoded by neurons 
through changes in their synaptic communications with other neurons, so-called synaptic 
plasticity. A prevailing model for how such changes occur is long-term potentiation 
(LTP) and depression (LTD) (see, e.g., (99, 100). Multiple disorders involving mental 
retardation such as Fragile X and Rett syndrome have been linked to proteins underlying 
synaptic plasticity (101, 102). OGT is present in the synapse and many postsynaptic 
proteins involved in LTP and LTD carry O-GlcNAc (see section 3.1 and 3.2). Using 
electrophysiology, it was further established that O-GlcNAc cycling is necessary for 
normal expression of LTP; pharmacological inhibition of OGT diminished LTP whereas 
OGA inhibition elevated LTP (7). The effect may relate to the synaptic relocation of the 
-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic (AMPA) receptor, the glutamate 
neurotransmitter receptor responsible for most fast synaptic transmission in the central 
nervous system (CNS). O-GlcNAc modifies CaMKII in close proximity to a 
phosphorylation site that regulates its activity (see section 3.2). CaMKII, in turn, is one of 
the major pathways that can induce the synaptic insertion of the AMPA receptor (7, 103). 
Interestingly, an OGT-dependent increase in AMPA receptor conductivity was absent in 
AMPA receptors where the main CaMKII phosphorylation site was mutated to alanine 
(104).  
 O-GlcNAc cycling is important for dynamic synaptic function at the presynapse. 
Acute OGA inhibition in vivo decreases paired-pulse facilitation (PPF). PPF is a 
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measurement of vesicle release of neurotransmitter. O-GlcNAc may regulate PPF via 
synapsin I. The presynaptic protein synapsin I is extensively modified by O-GlcNAc and 
inhibition of OGA increases the  phosphorylation of synapsin I (7). 
 The studies investigating the effect of O-GlcNAc on learning and memory have 
so far relied heavily upon pharmacological manipulation of OGT and OGA. 
Unfortunately, some of the drugs used are known to cause off-target effects in cells. This 
may explain some apparent contradictions in published results; one report argues that O-
GlcNAc does not affect basal synaptic (7) transmission whereas another does see a large 
effect on basal AMPA receptor function (104). For future research, it will be important to 
develop mouse models of O-GlcNAc function and focus on mechanisms for the way in 
which O-GlcNAc may underlie learning and memory. One good example is a recent 
study that compared wildtype CREB with an O-GlcNAc loss-of-function mutant of 
CREB. This study overexpressed these proteins in vivo and showed that the O-GlcNAc 
mutant enhanced CREB-dependent transcription of several synaptic plasticity associated 
genes as well as short-term memory in mice (8).  
1.5.3 Impaired O-GlcNAc cycling contributes to neurodegenerative disease 
Neurodegenerative disease is a collection of disorders that are characterized by general 
cognitive decline and loss of neurons and neuronal synapses. They become more 
common with age but early-onset variants exist (105, 106). Impaired O-GlcNAc cycling 
is implicated in the development of several types of neurodegenerative disease, including 
Alzheimer's, Parkinsonism and Huntington's (2, 9, 74, 97). The loci for the genes 
encoding OGT and OGA are linked to Parkinsonian dystonia and Alzheimer's disease, 
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respectively. In addition, OGA transcripts are alternatively spliced in the brain in patients 
with sporadic Alzheimer's (see sections 2.2-3).  
 Two pathological hallmarks of Alzheimer's disease are neurofibrillary tangles and 
amyloid plaques (74, 105). The neurofibrillary tangles consist of paired helical filaments 
of tau, a protein that is important for microtubuli stability. Tau is extensively modified by 
O-GlcNAc, including in the region that binds to microtubuli (9, 12). Results from both in 
vitro and in vivo experiments indicated that increasing O-GlcNAc on tau protected it 
from filament precipitation (11). O-GlcNAc may save tau from precipitating either 
directly or indirectly by protecting it from hyperphosphorylation (11, 66). Alzheimer's 
patients present with hyperphosphorylated and hypo-O-GlcNAc glycosylated tau. No O-
GlcNAc can be found on the tau tangles isolated from these patients (10). Importantly, in 
mouse models of neurodegenerative disease resulting from expressing mutant forms of 
tau prone to precipitate, elevating global O-GlcNAc, including O-GlcNAc on tau, by 
selectively inhibiting OGA pharmacologically, slowed symptom progression (11). 
Interestingly, the main constituent amyloid plaques, amyloid precursor protein (APP), is 
also modified by O-GlcNAc (107). 
 Alzheimer's disease is intimately associated with dysregulated glucose 
metabolism and insulin resistance (108, 109). Due to the regulation of O-GlcNAc by 
nutrient supply and metabolic hormones, OGT has emerged as a key nutrient sensor in 
cells (see section 2.2). Much of the toxicity associated with excessive intake of glucose is 
mediated by the hexosamine biosynthesis pathway, the same pathway that produces the 
O-GlcNAc donor substrate UDP-GlcNAc. Many forms of insulin resistance are also 
related to OGT (23). Overexpression of OGT can independently lead to insulin resistance 
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(48). From this perspective, impaired O-GlcNAc signaling represents a model, and 
pharmacological target, for how metabolic dysfunction may result in neurodegenerative 
disease.  
 O-GlcNAc may also be involved in neurodegenerative diseases other than 
Alzheimer's. For example, in transgenic models where a polyglutamine expansion of 
huntingtin (the protein that causes Huntington's disease) was overexpressed, deletion of 
OGT attenuated neuron loss while deletion of OGA exacerbated neuron loss (97). In 
addition, -synuclein, the protein found in lesions overrepresented in Parkinson's disease, 
carries O-GlcNAc in the region known to induce self-aggregation (12). It should also be 
noted that O-GlcNAc in other cell types becomes elevated from many different types of 
stress and that deletion of OGT makes cells more vulnerable to stress (30, 110).  
1.6 Synaptic plasticity underlies adaptive behavior 
Neuronal synapses, the cell-cell junctions over which neurons communicate, are formed 
and eliminated throughout life and their turnover has for decades been associated with the 
way neuronal circuits adapt to environmental challenges to optimize behavior (111, 112). 
In both humans and animals, early development is characterized by massive generation of 
new synapses. About half of all synapses are then lost during adolescence (112, 113). 
Most mature excitatory synapses occur on dendritic protrusions called spines and 
essentially all spines contain an excitatory synapse (114-116). In vivo imaging of 
individual spines for days to months has shown that adult spines are largely stable but a 
small subpopulation remains plastic (113, 117) and spine turnover is increased by novel 
experience (115, 118-120). While most new spines are thin and withdraw rapidly, some 
enlarge and form stable synaptic contacts (112, 113, 117, 121-124). In fact, the 
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stabilization of a subset of new spines correlates with behavioral performance in several 
different tasks in multiple animal species (123, 125-127). Rather than synapse formation 
or density, the selection of which spines are retained once formed has been suggested to 
match circuit architecture with behavioral needs (128). Without affecting spine 
formation, deleting -adducin, which regulates actin, perturbed the process by which 
nascent spines establish functional synapses and impaired long-term memory (129). 
Fragile X Syndrome, a common form of mental retardation, exhibits a higher than normal 
density of spines but more of them exhibit an immature morphology and their turnover is 
not affected by sensory experience (119, 130). Conversely, the protein Telencaphalin 
arrests the maturation of spines and its removal enhances several forms of learning (123, 
131).  
The association between learning and spine survival suggests that synaptic 
maturation is regulated by neuronal activity (112). Long-term synaptic potentiation (LTP) 
caused by repeated stimulation of excitatory synapses, a predominate model for encoding 
of learning and memory on a cellular level, protects activated spines from removal (132, 
133). Likewise, Hill and Zito induced LTP specifically on individual newly formed 
spines through glutamate uncaging and observed potent stabilization (134). While also 
causing some spines to be eliminated, LTP does not consistently lead to a lasting increase 
in overall spine density (114, 132, 135, 136). It is widely believed that LTP is caused by 
insertion of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors 
into the synaptic membrane. AMPA receptors are glutamate-gated tetrameric ion 
channels composed of different combinations of subunits GluA1-4 and conduct the 
majority of the fast excitatory neurotransmission in the brain (103). AMPA receptors may 
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not be obligatory for spine formation in early development as knocking out (KO) GluA1-
3 shortly after birth did not change spine density (137). However, knocking down GluA1-
3 increases the number of inactive presynaptic terminals and overexpression of the 
GluA2 as well as the GluA4 subunits recruits synapses (138-140). Nascent spines 
incorporate AMPA receptors within a few tens of minutes of formation and so-called 
'silent spines', where AMPA receptors cannot be detected, do not correspond to the age of 
the spine but only its size (123, 141-144). Live imaging has shown that the frequency of 
local postsynaptic calcium transients within seconds to minutes upon contact between a 
dendritic protrusion and an axon correlates with the retention of that contact (122). While 
blocking glutamate signaling did not affect these early events, it did arrest subsequent 
molecular organization of the spine, including decreasing its long-term stability (122, 
124, 133). AMPA receptor stimulation, rather than overall neuronal activity, can rescue 
the loss of spines that occurs upon removal of presynaptic inputs (111, 145). Similar to 
LTP, which occurs mainly at small spines, inhibiting AMPA receptor signaling decreases 
spine density by reducing the number of small and thin spines (114, 146-148). Long-term 
depression (LTD) of excitatory synapses involves synaptic removal of AMPA receptors 
and leads to fewer and smaller spines (114, 149). A downstream target of AMPA 
receptor-dependent regulation of spine maturation is actin, e.g. via modulation of the 
RhoA signaling cascade (148, 150).  
In addition to their effect on synapse number, the function of the synapse, once it 
is formed, is heavily modified by the absolute abundance and relative efficacy of the 
AMPA receptors in the synaptic cleft (103). In fact, recent evidence from in vivo imaging 
of AMPA receptor trafficking argues that in mature circuits, some experience-dependent 
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synaptic plasticity is based mostly on a relative change in AMPA receptor abundance 
rather than turnover of synapses (142). AMPA receptors undergo both activity-dependent 
and constitutive recycling to and from the synaptic plasma membrane. AMPA receptors 
reach the cell membrane via vesicle-mediated extrasynaptic exocytosis and then by 
lateral diffusion enter the synapse. It has also been hypothesized that some synaptic 
translocation occurs by direct insertion into the synapse (103, 151, 152). Upon 
endocytosis, the receptor can either recycle back to the plasma membrane or undergo 
lysosmal and proteasomal degradation (103, 153). 
 The trafficking of AMPA receptors is regulated by AMPA receptor-binding 
proteins such as protein 4.1N and protein kinase C-alpha-binding protein (PICK1) (153). 
Many AMPAR interactions occur through its C-terminal PSD95/Dlg1/ZO1 (PDZ) ligand, 
but also through a membrane-adjacent domain. The AMPAR cytoplasmic tail is modified 
by several posttranslational modifications, e.g. phosphorylation, ubiqutination and 
palmitoylation, which can affect both AMPA receptor channel properties and protein-
protein interactions (154). 
 The AMPA receptor functions in a context of its auxiliary subunits called TARPs 
(transmembrane AMPA receptor regulatory proteins). TARPs regulate AMPAR 
conductance and trafficking (155, 156). While some evidence shows that AMPA receptor 
translocation can occur independent of their C-terminal tails, behaviorally relevant 
trafficking likely depends on the C-terminus. For example, point mutations of specific 
phosphorylation sites in the C-terminus affect both LTP and memory retention (157-159).  
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 Experience-dependent trafficking of AMPA receptors can occur in a subunit-
specific manner (160). It has been suggested that GluA1 homomers move into the 
synapse first to be replaced later by more stable GluA2/A3 heteromers (159, 161).  
 Synapse formation and termination and AMPA receptor trafficking are multi-step 
processes where the stability, or maturity, and function of the spine are continuously 
surveyed by activity-dependent processes. Though many molecules that affect synapse 
number and function have been identified over the last decade, it is still unclear how 
these are regulated to refine information processing to optimize behavior (162). 
1.7 Feeding behavior is regulated by diverse neuronal circuits in the 
brain 
Eating disorders, including obesity, bring enormous emotional, physical and economic 
costs to society (163, 164). Feeding behavior is a consequence of personal habits, social 
cues and chemical factors associated with ingested food. Although it has been known for 
decades that particular feeding centers in the brain integrate this information to either 
promote or inhibit food intake, their function has remained elusive. The main difficulty 
lies in resolving the many categories of neurons that often have contrasting roles 
contained in these centers (165).  
 While disorders like anorexia and bulimia nervosa (AN and BN, respectively) 
have been correlated with abnormal activity of several neurotransmitters, the 
heterogeneity of affected brain circuits make a related change hard to interpret as 
causative or compensatory (166). For example, palatable food increases dopaminergic 
release in the nuccleus accumbens but so do aversive stimuli like restraint stress. 
Although dopamine is associated with reward pathways, antagonizing dopamine strongly 
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inhibits feeding mostly due to motor dysfunction in the neostriatum (167). The problem is 
magnified by the fact that non-invasive methodology applied in human studies like fMRI 
cannot distinguish between anorectic and obesogenic neurons as they often lie 
intermingled and in areas technically challenging to image with high resolution (168). 
The basic sciences, on the other hand, have described many peripheral hormones, e.g. 
leptin, that potently regulate food intake depending on the energy need of the body (169). 
Curiously, these hormones often affect brain regions that have been difficult to link to 
common eating disorders directly (170). 
 The current confusion over where in the brain the pathology behind eating 
disorders lies is reflected by the lack of available long-term treatment for any of the 
major eating disorders like AN, BN or binge eating disorder (BED). Anti-depressants 
modulating serotonin and cognitive behavioral therapy decrease the frequency of binge 
episodes in BN and BED in the first six months, but the patients quickly relapse and there 
is no change in their body weight. Data from clinics specializing in eating disorders show 
that available treatment options do not lead to improvement in core symptoms over a five 
year period (171, 172).  
 Recently developed methods in rodents to identify and manipulate genetically 
defined neurons make it possible to disentangle those neuronal circuits that mediate 
feeding behavior (165) . A case in point is the medial hypothalamus. In the medial 
hypothalamus, there are several types of neurons that have strong effects on food intake. 
Obesogenic Agouti-related peptide (AgRP) neurons are mixed with anorectic 
proopiomelanocortin (POMC) neurons in the arcuate nucleus, adjacent to the third 
ventricle (173). Cell-specific neuronal tracing and opto- and pharmacogenetic methods 
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have shown that these neurons respond in opposite directions, where AgRP become 
activated and POMC neurons become inactivated, upon the antecipation of caloric 
ingestion and signal through multiple downstream targets. Some targets appear to directly 
modulate ascending information from the gastrointestinal system while other targets 
relate to more complex, higher-order processing of food intake (165, 174, 175)).   
 The need for effective treatment of eating disorders is pressing. Obesity is one of 
the world's leading causes of morbidity and mortality. 7-10% of the female population 
suffer from some eating disorder as defined in psychiatry. The prevalence among males is 
increasing. In addition to being unable to keep a normal weight, a problem which is 
common also in the general population, diseases like AN and BN are associated with 
grave psychological despair, for example depression, anxiety and substance abuse. In 
fact, eating disorders have the highest mortality rate of all psychiatric disorders, many 
times above the normal, in large part due to suicide (170).  
Until now, progress in preventing and treating eating disorders has been stymied 
by a lack of techniques identifying defined networks of neurons. Without this knowledge, 
it is not possible to synthesize how the many disparate brain regions associated with food 












Most content (e.g. text, figures and experimental results) included here is modified from 
work that has been submitted for publication: 
1. Lagerlöf O, Slocomb JE, Hong I, Aponte Y, Blackshaw S, Hart GW, Huganir RL. The 
nutrient sensor OGT in PVN neurons regulates feeding. In press (Science)  
2.1 Abstract 
Maintaining energy homeostasis is crucial for the survival and health of organisms. The 
brain regulates feeding by responding to dietary factors and metabolic signals from 
peripheral organs. It is unclear how the brain interprets these signals. O-GlcNAc 
transferase (OGT) catalyzes the posttranslational modification of proteins by O-GlcNAc 
and is regulated by nutrient access. Here we show that acute deletion of OGT from 
αCaMKII-positive neurons in adult mice caused obesity due to overeating. The 
hyperphagia derived from the paraventricular nucleus (PVN) of the hypothalamus where 
loss of OGT was associated with impaired satiety. These results identify O-
GlcNAcylation in αCaMKII neurons of the PVN as a novel molecular mechanism that 
regulates feeding behavior. 
2.2 Results and Discussion 
Obesity is a major contributor to disease throughout the world (163). Currently, there is 
no successful and available treatment for the majority of obese patients. One of the genes 
most commonly linked to human obesity, Gnpda2, affects flux through the hexosamine 
biosynthesis pathway (HBP) (176-178). The HBP produces uridine-diphosphate:N-
acetylglucosamine (UDP-GlcNAc), which is the donor substrate for the enzyme O-
 32 
GlcNAc transferase (OGT). OGT cleaves UDP-GlcNAc and covalently attaches GlcNAc 
to the hydroxyl group of serine or threonine in nuclear and cytoplasmic proteins in β-
linkage (O-GlcNAc). Nutrient access directly via the HBP and metabolic hormones such 
as insulin regulate the activity of OGT (2, 58). Like many other human obesity genes, 
Gnpda2 is believed to act mainly in the brain (176, 177). Although OGT has been shown 
to be important for neuronal development, the role of OGT for mature brain function is 
almost completely unknown (6, 8, 179). To study the function of OGT in normal 
behavior we created conditional OGT knock out (KO) mice by crossing floxed OGT 
mice (OGTFl) with mice expressing a tamoxifen-inducible version of Cre recombinase 
under the αCaMKII promoter (αCaMKII-CreERT2). This cross enables acute brain-
specific deletion of OGT in αCaMKII-expressing neurons in adult mice, which we 
confirmed by immunohistochemistry, Western blotting and PCR (Fig. 2.S1). It has been 
reported previously that KO of OGT leads to lower cell number, probably due to 
impaired mitosis and in fact constitutive KO of OGT leads to early embryonic lethality 
(6, 40, 95, 110). In contrast, in postmitotic neurons, deletion of OGT did not affect cell 
number in vitro or in vivo (Fig. 2.S2A-B).  
 Acute and brain-specific loss of OGT in adult mice caused rapid weight gain (Fig. 
2.1A-B, 2.S3A-B). Within three weeks the amount of adipose tissue tripled whereas the 
lean weight had not changed as quantified by whole-body nuclear magnetic resonance 
(NMR) (fat mass: Wt n=7, 2.5 +/- 0.21 g; KO n=6, 8.3 +/- 0.86 g, Fig. 2.S3C-D). 
Measuring the increase of adipose tissue intra-abdominally, subcutaneously, and in the 
liver showed that the incorporation of fat was general and not particular to any specific 
body region (Fig. 2.S3E-G). Obesity can result from either excessive caloric intake or 
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insufficient energy expenditure. Daily food intake rapidly increased upon KO of OGT 
and plateaued at a level more than twice as high (Fig. 2.1C). If access to food was 
restricted to the same amount consumed by wildtype (Wt) mice (pair-feeding), the KOs 
retained normal body weight. When free access to food was re-introduced, the KOs 
quickly approached the weight of KO littermates who had been fed ad libitum throughout 
the experiment (Fig. 2.1D). In order to quantify food intake and energy expenditure 
simultaneously in real-time, we took advantage of comprehensive laboratory animal 
monitoring system (CLAMS). CLAMS confirmed that loss of OGT leads to hyperphagia 
(Fig. 2.S3H). Energy expenditure was actually increased, which is inconsistent with 
changes in energy expenditure contributing to the weight gain (Fig. 2.S3I). The 
accelerated energy expenditure resulted from, at least in part, hyperactivity (Fig. 2.S3J). 
As expected from a combination of hyperphagia and hyperactivity, knocking out OGT 
caused higher vO2 and vCO2 leading to a respiratory exchange ratio (RER) above 1 (Wt 
n=17, 0.94 +/- 0.004; KO n=20, 1.04 +/- 0.007, Fig. 2.S3K-M).  
 Daily food intake is a factor of both the size of each meal and meal frequency. A 
normal diurnal rhythm was preserved in OGT KOs where physical activity and food 
intake showed clear preference for dark hours in both Wts and KOs (Fig. 2.1E, 2.S4A-B). 
While there was no difference in meal frequency, loss of OGT increased meal size as 
well as meal duration (meal size: Wt n=268, 0.25 +/- 0.02 g; KO n=330, 0.42 +/- 0.02 g, 
Fig. 2.1E, 2.S4C-E). The point at which a meal is terminated depends on the total caloric 
content of the food but also non-caloric determinants of the food, mainly its volume and 
composition. When fed either regular carbohydrate-rich pellets or fat-based food paste 
with higher caloric density, the OGT KOs overate the same amount of calories (Fig. 
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2.S4F). This indicates that the hyperphagia did not correlate with the composition of the 
food or its volume but only with its total caloric content. Our observations suggest that 
OGT-dependent hyperphagia is caused by impaired meal termination due to uncoupling 
of caloric intake from caloric need.  
 Immunohistochemistry for OGT showed that within the core feeding circuitry, the 
major loss of OGT in the KO mice occurred in medial nuclei of the hypothalamus, most 
notably in the paraventricular nucleus (PVN) (Fig. 2.2A, 2.S5A). There was only minor 
loss of OGT from nuclei of the midbrain and the brainstem (Fig. 2.2A, 2.S5A). Taking 
advantage of αCaMKII-CreER+ x TdTFl mice and immunohistochemistry, we noticed that 
some αCaMKII PVN cells expressed thyroid-releasing hormone (TRH) and some 
Oxytocin (Fig. 2.S6A). Before any major weight gain, OGT deletion reduced the 
expression of TRH, as determined by in situ hybridization, in a subpopulation of cells in 
the PVN without affecting their viability, whereas several other known neuropeptides 
regulating feeding behavior were largely unaltered; proopiomelanocortin (POMC), 
cocaine and amphetamine regulated transcript (CART), orexin, agouti-related peptide 
(AgRP), neuropeptide Y (NPY), vasopressin (AVP) and oxytocin (TRH: Wt n=4, 40 +/- 
4.1 cells / 150 x 103 µm2; KO n=4, 23 +/- 2.9 cells / 150 x 103 µm2, Fig. 2.2B, 2.S6B-E, 
2.S7A) (165, 180). Next, we infected hypothalamic organotypic cultures with a virus that 
expresses GFP under the αCaMKII promoter and treated the explants with varying 
concentrations of glucose. The PVN retained its normal morphology and expression of 
neuropeptide during the extent of the experiment (about 2.5 weeks, Fig. 2.S8A). 
Immunohistochemistry for O-GlcNAc demonstrated that 1 h treatment with 5 mM 
glucose, simulating physiological and meal-derived fluctuations in glucose, increased O-
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GlcNAc in αCaMKII-positive cells (1 mM n=360, 134 +/- 10 intensity / cell (a.u.); 5 mM 
n=330, 211 +/- 12 intensity / cell (a.u.), Fig. 2.2C) (181-183). In contrast, there was no 
change in O-GlcNAc levels in neighboring αCaMKII-negative cells (Fig. 2.S8B). 
Incubation for 16 hours with 25 mM glucose raised the O-GlcNAc levels in αCaMKII 
cells to a larger extent (5 mM n=390, 156 +/- 9 intensity / cell (a.u.), 25 mM n=375, 298 
+/- 14 intensity / cell (a.u.), Fig. 2.S8C-D). Unlike cortex and the hippocampus where O-
GlcNAc levels mirror food intake it has recently been reported that fasting increased O-
GlcNAc in AgRP neurons, which has been proposed to be due to stimulation of OGT 
expression by ghrelin in these cells (58, 179, 182). In the PVN, fasting decreased O-
GlcNAc, but only in αCaMKII-positive cells (αCaMKII-positive cells: fed n=455, 158 
+/- 5 intensity / cell (a.u.); starved n=259, 81 +/- 6 intensity / cell (a.u.), Fig. 2.S8E). In 
addition, we compared the expression of the immediate early gene c-Fos in αCaMKII 
PVN cells in vivo in mice fed ad libitum or refed upon starvation. This enables us to 
characterize cellular responses to food intake as mice start eating after a period of 
starvation. We found that food intake appeared to activate αCaMKII cells in the PVN and 
that loss of OGT blocked this activation completely (Fig. 2.S8F-G). Thus, within the 
PVN, OGT activity is directly sensitive to fluctuations in energy availability in αCaMKII 
neurons and may be crucial for their normal response to food intake. 
 O-GlcNAc is highly expressed in neuronal synapses in the brain (3). We crossed 
αCaMKII-CreER+ x OGTFl/Wt x TdTFl mice to assess whether OGT regulates excitatory 
synaptic input onto αCaMKII PVN cells using whole-cell patch-clamp techniques. If 
deleting OGT attenuates excitatory input, it would explain, at least in part, how OGT 
regulates the activity of these cells. The mean capacitance of labeled cells averaged 
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around 15pF and did not differ between Wts and KOs (Fig. 2.S9A). The mean miniature 
EPSC (mEPSC) frequency was more than three-fold lower in OGT KO cells (Wt n=6, 
1.7 +/- 0.11 Hz; KO n=6, 0.50 +/- 0.10 Hz, Fig. 2.3A-B). The mean mEPSC amplitude 
was also decreased but to a much smaller degree (Wt n=6, 19.7 +/- 1.16 pA; KO n=6, 
15.6 +/- 0.867 pA, Fig. 2.3A, 2.3C). Waveform analysis showed that neither the rise time 
nor the decay time of the EPSCs changed upon deleting OGT (Fig. 2.S9B-C). 
Pharmacological inhibition of glutamatergic signaling in the PVN has been shown 
previously to elicit intense feeding (18). The sharp decrease in mEPSC frequency 
suggests that OGT is essential for maintaining the number of functional excitatory 
synapses onto αCaMKII PVN neurons. 
 Selectively deleting OGT in the αCaMKII cells of the PVN by stereotactic virus 
injection caused concurrent obesity and hyperphagia (Fig. 2.4A-C, 2.S9D). As deletion of 
OGT in αCaMKII cells in the PVN prevents their feeding-induced activation and leads to 
hyperphagia, we predicted that stimulating those cells would decrease food intake. 
Activating αCaMKII PVN cells optogenetically decreased cumulative food consumption 
over 24 h (baseline n=11, 3.6 +/- 0.14 g; 50 Hz n=11, 2.6 +/- 0.33 g, Fig. 2.4D-E) (184). 
Consistent with OGT’s regulation of meal size, the main change in food intake came 
from smaller amounts of food ingested per meal while there was no significant effect on 
meal frequency (meal size: baseline n=125, 0.25 +/- 0.014 g; 50 Hz n=110, 0.20 +/- 0.014 
g, Fig. 2.4F, 2.S9E). In a second experiment, we started the stimulation at the onset of 
darkness after fasting the mice during the light phase to assay whether activation of these 
cells is able to override hunger-induced feeding. Fasting increased food intake and 20 Hz 
optogenetic stimulation for 4 hours produced a significant decrease in food intake, while 
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50 Hz stimulation for 1 or 4 hours produced large significant drops in feeding (Fig. 
2.S9F). The decrease in meal size with 50 Hz stimulation was evident in the first meal 
without any change in latency to initiation of feeding (Fig. 2.S9G-H).   
 Together, our data favor a model where the function of OGT is to couple energy 
intake with energy need, at least in part, by regulating the excitatory synaptic input in 
αCaMKII PVN cells (Fig. 2.4G). The select effect on meal termination suggests that 
OGT regulates satiation. αCaMKII neurons are often excitatory. Although vGlut2-
positive excitatory neurons in the PVN decrease food intake, there appears to be only 
partial overlap between αCaMKII and vGlut2 expression in the PVN (185, 186). As 
glucose remains elevated in the cerebrospinal fluid more than 1 h upon eating, the 
feeding-related changes in O-GlcNAc integrates nutrient availability on a time scale 
longer than a single meal (181, 187). The brain promotes satiation by coordinating 
adipokines reflecting body energy depots and acute food-derived signals into circuits that 
turn off feeding. Rather than constituting a link in meal-to-meal satiety feedback loops, 
our observations suggest that OGT controls the threshold of such loops through its 
regulation of excitatory synaptic transmission onto αCaMKII PVN neurons. The 
observation that OGT KOs quickly reached a plateau in daily food intake supports this 
idea. Thresholding satiation between meals confers the behavioral advantage of 
stabilizing caloric intake over time such that the previous meal informs on the caloric 
need of the next. These data do not exclude additional, faster regulation of OGT activity 
and levels via metabolic hormones. In conclusion, the findings of this paper identify the 
regulation of excitatory synapses onto αCaMKII PVN neurons by OGT as a novel 







Fig. 2.1. Acute deletion of OGT in αCaMKII-positive neurons causes hyperphagia-
dependent obesity. (A) Photo of mice four weeks after OGT deletion. (B) Body weight 
time course (Wt n=8, KO n=8; repeated-measures two-way ANOVA with post hoc 
Bonferroni test: P<0.05). (C) Daily food intake time course (Wt n=6, KO n=6; repeated-
measures two-way ANOVA with post hoc Bonferroni test: P<0.05). (D) Body weight 
time course upon pair-feeding (free n=4, restricted n=4, Wt n=3). (E) Food intake every 











Fig. 2.2. OGT-mediated hyperphagia is associated with feeding circuitry function in 
the PVN. (A) αCaMKII expression within feeding circuitry (schematized from Fig. 
S5A). (B) TRH expression. Left; image of probe staining, right; quantification (Wt n=4, 
KO n=4; two-tailed t-test: P<0.05). (C) Left; GFP and O-GlcNAc in the PVN. Right; 
quantification of O-GlcNAc intensity in GFP-positive cells (1 mM n=240, 5 mM n=270; 














Fig. 2.3. OGT regulates excitatory synaptic function in αCaMKII PVN neurons. (A) 
Sample traces from Wt and KO cells. (B-C) mEPSC frequency (B) and amplitude (C) in 
αCaMKII-positive PVN neurons (Wt n=6, KO n=6; two-tailed t-test: P<0.05). 



















Fig. 2.4. OGT regulates feeding behavior in αCaMKII neurons of the PVN. (A) Top; 
schematic of stereotactic PVN injection. Bottom; GFP expression in the PVN after 
stereotactic injection. (B-C) Body weight (B) and daily food intake (C) time course (Wt 
n=5, KO n=7; repeated-measures two-way ANOVA with post hoc Bonferroni test: 
P<0.05). (D) Schematic of optogenetic setup with αCaMKII-driven expression of 
channelrhodopsin-2 in the PVN with the abutting laser. (E-F) Food intake after 
optogenetic stimulation. (E) 24 h cumulative food intake. Bars represent average intake 
over all mice and lines represent average intake per individual mouse. (baseline n=11, 
stimulation n=11; two-tailed t-test: P<0.05). (F) Average meal size (baseline n=125, 
stimulation n=110; two-tailed t-test: P<0.05). (G) Model of OGT-dependent hyperphagia. 





Fig. 2.S1. αCaMKII-CreER x OGTFl deletes OGT in αCaMKII-positive neurons of 
adult mice but does not affect OGT expression in peripheral organs. (A) Schematic 
of the Ogt locus, including loxP sites (triangles) in OGTFl mice and translational start site 
(empty circle). (B) PCR analysis showing the genotype of Wt (αCaMKII-CreER- x 
OGTFl) and KO (αCaMKII-CreER+ x OGTFl) mice. (C) Immunohistochemistry for OGT. 
Top: neocortex. Bottom: the hippocampus. (D) Primary cultured OGTFl neurons were 
infected with either a wildtype (Wt) virus or a virus expressing Cre recombinase (KO). 
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Western blot characterizing the O-GlcNAc and OGT expression in Wt and KO neurons. 
(E) Western blot characterizing O-GlcNAc and OGT expression in peripheral tissues. (F) 
Quantification of OGT expression in peripheral tissues from (E) (Wt n=7, KO n=8; two-
tailed t-test: P<0.05). (G) PCR analysis detecting Cre-dependent Ogt recombination in 

























Fig. 2.S2. Deletion of OGT in postmitotic neurons does not affect cell number. (A) 
Left: DAPI stain of primary cultured neurons that were infected with either a wildtype 
virus (Wt) or a virus expressing Cre recombinase (KO). Right: quantification of DAPI 
stained cells (Wt n=3, KO n=3; two-tailed t-test: P<0.05). (B) Left: DAPI stain of the 
CA1 region of the hippocampus, where almost all cells express αCaMKII. Right: 
quantification of DAPI stained cells (Wt n=3, KO n=3; two-tailed t-test: P<0.05). 








Fig. 2.S3. Loss of OGT leads to adiposity, hyperphagia and hyperactivity. (A-B) 
Induction of Cre recombinase by tamoxifen treatment leads to weight gain only in the 
presence of floxed Ogt. (A) Quantification of body weight; tamoxifen treatment alone 
does not affect body weight (n=3 for all groups; one-way ANOVA with post hoc Tukey’s 
Multiple Comparison Test: P<0.05). (B) Quantification of body weight;  αCaMKII-
CreER crossed with an unrelated floxed mouse and treated with tamoxifen does not affect 
body weight (Wt n=5, KO n=5; two-tailed t-test: P<0.05). (C-D) Quantitative NMR of 
total body fat (C) and total lean body mass (D) (Wt n=7, KO n=6; two-tailed t-test: 
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P<0.05). (E-G) Quantification of amount fat in different regions the body. (E) 
Intraperitoneal fat. (F) Subcutaneous fat. (G) Total liver weight. (For all regions: Wt n=3, 
KO n=3; two-tailed t-test: P<0.05). (H-M): Data from CLAMS analysis; (H) Daily food 
intake. (I) Total energy expenditure as measured by exchange of respiratory gases, see 
Methods. (J) Physical activity. (K) Volume O2 inhaled. (L) Volume CO2 exhaled. (M) 
The respiratory exchange ratio (RER). (H-M: Wt n=17, KO n=20; two-tailed t-test: 





















Fig. 2.S4. Diurnal rhythm and meal frequency are not perturbed in OGT KO mice 
while meal size and duration are increased. The OGT-dependent hyperphagia 
correlates with total caloric intake. (A) Quantification of total activity during CLAMS 
as dispersed over dark and light hours (Wt n=21, KO n=21; two-tailed t-test: P<0.05). (B) 
Quantification of food intake during CLAMS as dispersed over dark and light hours (Wt 
n=17, KO n=20; two-tailed t-test: P<0.05). (C) Quantification of the number of initiated 
meals during CLAMS (Wt n=17, KO n=20; two-tailed t-test: P<0.05). (D-E) 
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Quantification of meal size (D) and meal length (E) during CLAMS (Wt n=268, KO 
n=330; two-tailed t-test: P<0.05). (F) Quantification of food intake as it differs between 
carbohydrate-based pellets and fat-based paste (KD). (Chow (3.1 kcal/g): Wt n=10, KO 
























Fig. 2.S5. αCaMKII-CreER x OGTFl deletes OGT from several core feeding nuclei. 
(A) For each panel: left; immunohistochemistry for OGT in αCaMKII-CreER x OGTFl 
mice. Arrowheads indicate cells that lack OGT. Right; schematics showing general 
anatomical landmarks for slices that were used for imaging. The areas within each slice 
containing purple dots were the areas that were imaged and used for analysis. Purple dots 
within the schematics indicate cells that lost OGT in KO mice. Abbreviations used: 
Paraventricular nucleus (PVN), Dorsomedial hypothalamic nucleus (DMH), Arcuate 
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nucleus (Arc), Ventromedial hypothalamus (VMH), Lateral hypothalamus (LH), Nucleus 



























Fig. 2.S6. αCaMKII-CreER x OGTFl deletes OGT from a subpopulation of cells in 
the PVN with no effect on total cell number in the PVN. (A) αCaMKII-positive cells 
(purple) were labeled using αCaMKII-CreER+ x TdTFl mice. Left: DAPI (green). Middle: 
immunohistochemistry for TRH (green). Right: immunohistochemistry for Oxytocin 
(green). Arrow; cell positive for both the cell-specific marker and TdT. Arrowhead; cell 
positive for the cell-specific marker but not TdT. (B) Double-labeling of TRH cells and 
αCaMKII cells. The PVN was injected stereotactically with Wt or KO virus. TRH cells 
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were labeled with immunohistochemistry for TRH (purple) and αCaMKII cells with virus 
expressing GFP under the αCaMKII promoter (green). Arrow; cell positive for both TRH 
and GFP. Arrowhead; cell positive for TRH but not GFP. (C) Serial sections of the PVN 
were cut and subjected to in situ hybridization for TRH as shown in Fig. 2B. Shown is 
the quantification of the number of TRH positive cells per PVN slice. The distribution of 
TRH cells in Wts and KOs showed statistical un-equal variance, indicating that a 
particular subpopulation of TRH cells is affected by OGT deletion (Wt n=45, KO n=48; 
F-test: P<0.05). (D) The same data as in (C) but plotted is the number of TRH positive 
cells per PVN slice in relation to distance from Bregma. (E) Left: DAPI stain of the PVN. 
Right: quantification of DAPI stained cells (Wt n=3, KO n=3; two-tailed t-test: P<0.05). 

















Fig. 2.S7. Deletion of OGT in αCaMKII-positive neurons leaves several major 
feeding circuits intact. (A) In situ hybridization for neuropeptide modulators in core 
feeding circuits two weeks after OGT KO prior to significant weight increase. For each 
peptide: left; image of probe staining, right; quantification of number of stained cells 
within the respective area (cells / 150 x 103 µm2) and quantification of intensity of 
staining per cell (a.u.) (Wt n=4 (except for CART, and number of oxytocin positive cells, 










Fig. 2.S8. αCaMKII-positive PVN neurons are uniquely sensitive to physiological 
variations in glucose in terms of O-GlcNAc and deletion of OGT blunts feeding-
induced activation of the same cells. (A-D) Hypothalamic explant with GFP expression 
(green) and immunohistochemistry for TRH (A) or O-GlcNAc (C) (purple). Boxed 
magnification in (A) shows the PVN. (B) Quantification of O-GlcNAc intensity in 
αCaMKII-negative cells in the PVN from Fig. 2C (1 mM n=360, 5 mM n=330; two-
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tailed t-test: P<0.05). (D) Quantification of O-GlcNAc intensity in αCaMKII-positive 
cells in the PVN from (C) (5 mM n=390, 25 mM n=375; two-tailed t-test: P<0.05). (E) 
O-GlcNAc expression in the PVN in fed and starved animals (αCaMKII-CreER+ x TdTFl 
mice). Left; double-labeling of TdT expression (purple) and immunohistochemistry for 
O-GlcNAc (green). Arrow; cell positive for TdT. Arrowhead; cell negative for TdT. 
Right; quantification of O-GlcNAc expression in TdT-positive and TdT-negative cells 
(TdT-positive: fed n=455, starved n=259. TdT-negative: fed n=357, starved n=375; two-
tailed t-test: P<0.05). (F) The PVN was injected stereotactically with Wt or KO virus. 
Double-labeling of GFP expression (green) and c-Fos (orange) in the PVN in fed and 
refed animals. Arrow; cell positive for both c-Fos and GFP. Arrowhead; cell positive for 
c-Fos but not GFP. (G) Quantification of number of cells expressing both GFP and c-Fos 
from (F) (Fed: Wt n=8, KO n=7. Refed: Wt n=12, KO n=10; two-tailed t-test: P<0.05). 
















Fig. 2.S9. OGT KO does not affect membrane capacitance or EPSC shape in 
αCaMKII-positive cells in the PVN and optogenetic stimulation of the same cells 
decreases food intake. (A-C) Patch-clamp analysis of αCaMKII-positive cells in the 
PVN (Wt n=6, KO n=6; two-tailed t-test: P<0.05). (A) Membrane capacitance. (B) 
mEPSC peak rise time. (C) mEPSC peak decay tau. (D) GFP expression (green) and 
immunohistochemistry for OGT (purple) in the PVN after stereotactic injection of Wt or 
KO virus. Arrow; cell positive for OGT and GFP. Arrowhead; cell positive for OGT 
only. (E-H) Optogenetic stimulation of αCaMKII-positive cells in the PVN. (E) 
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Quantification of meal frequency (baseline n=11, stimulation n=11; two-tailed t-test: 
P<0.05). (F) Quantification of food intake after a light fast. Bars represent average intake 
over all mice and lines represent average intake per individual mouse (All conditions 
n=5; two-tailed t-test: '*' refers to P<0.05). (G) Quantification of the size of the first meal 
after a light fast, 50 Hz stimulation (baseline n=5, stimulation n=5; two-tailed t-test: 
P<0.05). (H) Quantification of the latency to the initiation of the first meal after a light 
fast, 50 Hz stimulation (baseline n=5, stimulation n=5; two-tailed t-test: P<0.05). 















2.3 Materials and Methods 
Animals 
 OGTFl and αCaMKII-CreERT2 mice have been derived previously(6, 188). They 
were fully backcrossed (>N11) to the C57BL6 background. Only males were used and 
they were about 6 weeks old at the start of experiments. Tamoxifen was injected 
accordingly: 2mg twice per day for 5 days (20mg total dose). Control mice were either 
vehicle (sunflower seed oil injected into OGTFl x αCaMKII-CreER+ mice) or genetic 
(tamoxifen injected into OGTFl x αCaMKII-CreER-) controls. No difference between 
controls was seen. Therefore, all control animals were combined. Mice were fed standard 
chow (Teklad Global 2018SX: 24% protein, 18% fat, 58% carbohydrate) and had free 
access to food unless otherwise specified. Only littermates were compared. Apart from 
noted exceptions, the animals were kept on a 14 h/10 h light/dark cycle. For all animal 
studies, animals where randomly allocated to experimental groups. The experimenter was 
aware of the animal genotype when conducting experiments. The TdTFl mice express the 
fluorescent reporter TdTomato upon exposure to Cre recombinase and were originally 
developed by the Allen Institute (Ai9). All animals were housed according with the Johns 
Hopkins University Animal Care and Use Committee guidelines. All details pertaining to 
optogenetics experiments, including animal work, are described below under 
Optogenetics. 
Biochemistry 
 Primary neuronal cell culture. Cortical neurons were prepared from timed E18 
embryos, as previously described (189). Lentivirus was added at DIV (days in vitro) 2. 
Cells were harvested for analysis at DIV 11-13.  
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 Western blot. Cultured cells were harvested in RIPA buffer (50mM tris, 150mM 
sodium chloride, 1% NP-40, 1% deoxycholate, 0.1% SDS, 1mM EDTA, including 
inhibitors for proteases, phosphatases and O-GlcNAcases), solubilized for 20 min at 4°C 
and then spun at 13000 rpm. The supernatant was used for further analysis. When tissue 
was analyzed, unless otherwise noted, after removal from the animal, it was homogenized 
in homogenization buffer (HB; 0.32M sucrose, 10mM HEPES, including inhibitors for 
proteases, phosphatases and O-GlcNAcases ). 2X RIPA was then added to a final 
concentration of 1X RIPA for solubilization at 4°C for 20 min, before spun at 13000 rpm. 
Clear lysate, with top lipid layer discarded, was used for further analysis. Note that the 
muscle indicated in Fig. 2.S1A is musculus femoris. Western blotting was performed 
according to standard procedures. Briefly, after separation by SDS-PAGE and transfer to 
polyvinylidene fluoride (PVDF) membranes, membranes were blocked in 3% bovine 
serum albumin (BSA), or 5% bovine milk when blotting for O-GlcNAc, and then probed 
with the following antibodies: OGT (AL25, produced in-house, 1:5000), O-GlcNAc 
(CTD110.6, produced in-house, 1:10000), HSC70 (Santa Cruz Biotechnology, sc7298, 
1:5000). 
Virus 
 For cell culture experiments, lentivirus was used. VSVG pseudotyped lentiviral 
particles were produced by standard procedures. In short, a FUGW vector expressing 
enhanced (eGFP) alone (Wt) or eGFP and Cre recombinase (KO) together with cDNA 
plasmids VSVG and delta 8.9 were transfected into HEK 293T cells using Lipofectamine 
(25). The culture supernatant was collected 24 h and 48 h after transfection, then 
subjected to ultracentrifugation where the resulting pellet was resuspended in Neurobasal 
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medium. For viral infections in vivo, adeno-associated virus (AAV) was used. All AAV 
were of serotype 2.1 and purchased from University of Pennsylvania Vector Core: For 
Wt; #AV-1-PV1917 (AAV1.CaMKII0.4.eGFP.WPRE.rBG) and for KO; #AV-1-PV2521 
(AAV1.CaMKII.HI.eGFP-Cre.WPRE.SV40). All details pertaining to optogenetics 
experiments are described below under Optogenetics. 
Histology 
 Immunohistochemistry. Animals were anesthetized with avertin (0.03ml/g) and then 
perfused with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS). The 
brain was removed and post-fixed in 4% PFA/PBS overnight. After the brain had been 
equilibrated in 30% sucrose/PBS, it was frozen and serial sections (25 µm) were cut on a 
microtome (Leica, SM2000R). Free-floating sections were blocked in IHC buffer (5-10% 
normal goat serum diluted in 0.25% triton X-100/PBS) overnight at 4°C, incubated with 
the primary antibody overnight at 4°C and then with the secondary antibody either for 2 
hours in room temp or overnight at 4°C. DAPI was included with the secondary antibody. 
Washes after the primary and secondary antibody were done in 0.25% triton X-100/PBS 
and antibodies were diluted in IHC buffer. Primary antibodies used were OGT (AL25 
(produced in-house), 1:5000), TRH (Santa Cruz Biotechnology, 1:100), c-Fos (ABE457, 
Millipore, 1:500), Oxytocin (MAB5296, Millipore, 1:1000), GFP (Abcam, 1:1000), in 
Figs. 2.4 and 2.S9 the signal from virally expressed GFP alone was imaged without using 
an antibody against GFP. For some experiments when staining for OGT alone, the animal 
was not perfused but fixed in 4% PFA/PBS overnight.  
 In situ hybridization. The brain was removed and fresh frozen in OCT (Tissue-Tek) 
and stored at -80°C. Serial sections were cut (25 µm) on a cryostat (Leica CM3050-S) 
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and stored at -80°C. Probes and hybridization protocol have been described at length 
previously (190, 191). Briefly, slides were fixed in 4% PFA,  treated with acetic 
anhydride and then blocked in pre-hybridization solution (hybridization buffer without 
probes added: 50% formamide, 5X saline sodium citrate (SSC), 5X Denhardt’s solution 
(Bioworld), 250ug/ml yeast tRNA, 500ug/ml sperm DNA) before application of 
respective probe diluted in hybridization buffer. Hybridization was done at 70°C 
overnight. The next day the slides were washed, re-blocked (0.1M Tris, pH 7.5, 0.15M 
sodium chloride, 5% sheep serum) and then incubated overnight at 4°C with an alkaline-
phosphatase linked anti-digoxigenin antibody (Roche, 1:5000) diluted in blocking buffer. 
On the third day probes were developed after washing. Probe development was done by 
applying a mix of NBT (nitro-blue tetrazolium chloride), BCIP (5-bromo-4-chloro-3'-
indolyphosphate p-toluidine salt) and levamisole until sufficient stain had precipitated 
(within the same probe, all slides were treated for the same length of time). Afterwards, 
slides were DAPI stained.  
 Brain region coordinates. Different brain regions were identified by taking 
advantage of the Paxinos and Franklin atlas (The Mouse Brain, in stereotaxic coordinates, 
second edition). Counted as distance from Bregma, the following coordinates were used: 
SCN (-0.34 to -0.82), PVN (-0.60 to -1.20), Arc (-1.46 to -2.20). VMH (-1.30 to -2.06), 
LH (-1.34 to -1.75), DMH (-1.46 to -2.06). The PBN and the NTS were identified on 
sagittal slices, PBN (Bregma: -5.00 to -5.45, lateral: 0.85 to 1.35), NTS (Bregma: -6.30 to 
-7.80, lateral: 0.36 to 0.96). Abbreviations used: Paraventricular nucleus (PVN), 
Dorsomedial hypothalamic nucleus (DMH), Arcuate nucleus (Arc), Ventromedial 
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hypothalamus (VMH), Lateral hypothalamus (LH), Nucleus of the solitary tract (NTS), 
Parabrachial nucleus (PBN). 
Organotypic cultures 
 Acute coronal slices were cut from male mice around postnatal day 10 on a 
vibratome. The slices were cut in oxygen-bubbled dissection medium (1 mM CaCl2, 5 
mM MgCl2, 10 mM glucose, 4 mM KCl, 26 mM NaHCO3, 218 mM sucrose, 1.2 mM 
NaH2PO4(H2O), 30 mM HEPES). After cutting, the dorsal half of each slice was 
removed and then mounted on membrane inserts in a 6 well plate (one slice per insert). 
Each well was filled with 1 ml slice culture media (SCM: 4.16 g/500ml MEM, 20% horse 
serum, 1 mM L-glutamine, 0.5 mg/500ml insulin, 2 mM MgCl2, 1 mM CaCl2, 3 mM 
glucose, 1.3 mM NaHCO3, 3.58 g/500ml HEPES) and changed every 2-3 days. Explants 
were incubated at 35 °C. On DIV 10, virus was added by direct application on the top of 
each slice to label αCaMKII-positive cells (UPenn, #AV-1-PV1917 
(AAV1.CaMKII0.4.eGFP.WPRE.rBG)). After about 1 week, cultures were submitted to 
1 mM glucose SCM for 24 h (media changed once during those 24 h) and then changed 
into either fresh 1 mM or 5 mM glucose SCM for 1 h. In a second round of experiments, 
slices were put in 5 mM glucose SCM for 24 h and then transferred to either fresh 5 mM 
or 25 mM glucose SCM for 16 h. Slices were then fixed in 4% PFA in PBS for 2-7 h. The 
area around the fixed slices were cut out using a scalpel and then subjected to 
immunohistochemistry (O-GlcNAc and TRH) as described for free-floating slices. 
Stereotactic virus injection 
 Anesthesia was induced using avertin (0.03ml/g) and thereafter kept by 1-1.5% 
isoflurane gas inhalation. The coordinates for the PVN were: distance from Bregma, -
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0.80 mm; distance from midline, 0.20 mm; depth from surface, -4.75mm. The stereotaxic 
instrument used was the Leica Angle Two stereotaxic instrument. The scalp was exposed 
by a small incision through the skin. Bregma and Lambda were identified and two small 
holes drilled over the injection site. Stored virus was thawed, diluted with sterile saline to 
a final concentration of 1x109 particles/ul and then spun for 5 min at 3000 rpm in room 
temperature. The virus was then loaded into a pulled glass pipette (20-40 µm) and 
connected to a syringe pump (WPI, sp220i). In total, 2ul virus was injected at 0.300 
ul/min. After the surgery, the scalp was sutured and the animal rehydrated with saline 
(0.02 ml/g, intraperitoneal injection) and given buprenorphine to relieve pain (0.01 ml/g, 
subcutaneous injection). Upon animal harvest, the injection site and spread of the virus 
was controlled by immunohistochemistry. In total, 5 Wt animals and 8 KO animals were 
injected. In all but one case, the PVN was successfully targeted. Although there was 
minor spread outside the PVN, the PVN was the common denominator of areas hit across 
animals. In the one case when the PVN was hit only partially, the daily food intake and 
body weight increased but to a lesser degree, as expected (data not shown). This animal 
was removed from analysis. Excluding animals where the PVN had not been successfully 
targeted was a pre-established criterion. All details pertaining to optogenetics 
experiments are described below under Optogenetics.  
Behavior 
 General feeding behavior. Animals were kept in individual cages after tamoxifen 
treatment or virus injection. Food intake was measured by weighing leftover food pellets. 
The bottom of the cage was searched to include all leftover food. For some Wt and KO 
tamoxifen treated animals, the animals were not separated to individual cages until two 
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weeks after the treatment had finished. Data from these animals were compiled with the 
rest as the effect on feeding behavior and body weight for all animals followed the same 
time course. Whereas tamoxifen treated animals were kept on a 14 h/10 h light/dark 
cycle, the virus injected animals were kept on a 12 h/12 h light/dark cycle. 
 Restricted feeding. 10 days after tamoxifen treatment, the KO animals were split into 
two groups. One group had continuous free access to food whereas the other group was 
fed 1 gram at the start of light hours and 2.5 grams at the start of dark hours, totaling 3.5 
grams/day. At 21 days, free access to food was reintroduced to the latter group. Animals 
were kept on a 12 h/12 h light/dark cycle. 
 Comprehensive laboratory animal monitoring system (CLAMS). CLAMS (Columbus 
Instruments) is a closed chamber system that measures ventilation gases and food intake 
automatically. Our system was also equipped with laser beams that register physical 
movement. We submitted 7 Wt and 7 KO mice to CLAMS analysis two weeks after 
tamoxifen treatment. After several days of acclimatization, data were collected for 3 
days. Data were binned in 15 min increments. Values that were the obvious result of 
aberrant mouse behavior or technical failure, such as spillage off the scale, were removed 
from analysis. There were a few small negative values recorded. These were included in 
the analysis, except for Fig. S.1E for which negative values were removed. The total 
number of beam breaks is shown as ‘physical activity’ in all figures. A ‘meal’ was 
defined as any multiplicative of 15 min where the amount of intake the first 15 min was 
50 mg or larger and the previous 15 min had no intake registered. A meal was considered 
finished when no intake had been registered for another 15 min. The formulas used to 
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calculate different endpoints can be found at www.colinst.com. Animals were kept on a 
12 h/12 h light/dark cycle. 
 Refeeding. For refeeding experiments in Fig. 2.S8, the food was removed for 24 h 
and then reintroduced for 2.5 h before animal harvest. Throughout the experiment, the 
animals had free access to drinking water. For the refeeding paradigm coupled with 
optogenetics, see Optogenetics. 
 Fat-based diet. Mice were fed either regular chow (3.1 kcal/g, Teklad Global 
2018SX: 24% protein, 18% fat, 58% carbohydrate) or energy-dense fat-based food (6.7 
kcal/g, Teklad Global TD.96355: 9.1% protein, 90.5% fat, 0.4% carbohydrate). The mice 
were raised on regular chow and then switched to fat-based diet either about 1 week 
before injected with tamoxifen or about 14 days after injections had finished. The same 
behavior was noticed in both regiments and the data were combined. As the data for 
regular chow mimicked the data in general feeding behavior experiments, all those data 
were combined also. The data shown are the averages during the period when daily food 
intake had stabilized (days 20-26 after tamoxifen injection). 
Optogenetics 
 Animals. All experimental protocols were conducted according to U.S. National 
Institutes of Health guidelines for animal research and were approved by the Institutional 
Animal Care and Use Committee at NIDA.  Male C57BL/6J mice (2–5 months old, 
Jackson Laboratories) were used for optogenetic experiments. 
 Stereotactic viral delivery and fiber guide system implantation. Mice were 
anesthetized with isoflurane and were placed into a stereotaxic apparatus (David Kopf 
Instruments), as previously described (192). A pulled glass pipette with 30-40µm tip 
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diameter was inserted into the brain, and one unilateral injection (30nL) of AAV2/1-
CamKIIα-hChR2(H134R)-EYFP virus (titer: 3.3x1012 viral genomes/mL, Optogenetics 
and Transgenic Technology Core, NIDA) was made at coordinates in the paraventricular 
nucleus of the hypothalamus  (PVN, bregma: -0.70mm, midline: +0.15mm, dorsal 
surface: -4.60mm).  A micromanipulator (Narishige) was used to control the injection 
speed (30nL/min), and the pipette was withdrawn 15 min after the injection.  This was 
followed by the insertion of a ferrule-capped optical fiber (200 μm diameter core; 
BFH48-200-Multimode, NA 0.48; Thorlabs) through the craniotomy.  Metabond cement 
(C&B-METABOND Quick! Cement System, Parkell, Inc.) was used to anchor the ferrule 
to the skull.  The fiber tip was implanted 0.7mm above the PVN.  Mice were returned to 
their home cages for 10 – 14 days to recover and for expression of ChR2:EYFP. 
 Components for food consumption and photostimulation. In home cages, mice had 
ad libitum access to rodent chow (PicoLab Rodent Diet 20, 5053 tablet, TestDiet). For 
behavioral testing, mice were transferred into feeding cages with automatic pellet 
dispensers (Coulbourn Instruments) and supplied with food pellets (20 mg each) of 
identical composition to the food in the home cage. Pellet removal was sensed by the 
offset of a beam break and an additional pellet was administered after a delay (10 s). 
Food consumption was monitored continuously using Graphic State software (Coulbourn 
Instruments). Water was also available ad libitum during behavioral experiments, and in 
some cases, was monitored by optical detection (Coulbourn Instruments) of licks emitted 
towards the drinking spout. In addition, water bottles were manually weighed to estimate 
water intake every 24 hours. Mice were allowed to acclimate for 3 days before initiating 
the photostimulation protocols. Light was delivered to the brain through an optical fiber. 
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The relationship of light scattering and absorption in the brain as a function of distance 
has been described previously (Aravanis AM, et al., 2007). Using this relationship, the 
light power exiting the fiber tip (10 mW) was estimated to correspond to 2.0 mW/mm2 at 
the PVN, which was sufficient to drive a behavioral response. For optical delivery of 
light pulses with millisecond precision to multiple mice, the output beam from a 300 mW 
diode laser (473 nm, Opto Engine, LLC) ) was split into four beams using a combination 
of 50/50 beam splitters and turning mirrors (Thorlabs). Each beam was controlled using 
an acousto-optic modulator (AOM) (Quanta Tech OPTO-ELECTRONIC) to generate 
light pulses that were launched into separate fiber ports (PAF-X-7, Thorlabs) and their 
corresponding optical fibers. Using these components, four mice could be simultaneously 
and independently photostimulated. LabVIEW software (National Instruments) was used 
control the AOMs. 
 Behavioral experiments. General feeding behavior. Food intake was recorded during 
a pre-stimulus (baseline) for 3 days followed by a 24 h photostimulation period. In two 
experiments, stimulation started during light hours and in one experiment stimulation 
started at the onset of darkness. In all experiments, the same behavioral response was 
recorded and the data were averaged over all experiments. The primary photostimulation 
protocol consisted of 50 light pulses (10 ms) for 1 s at 50 Hz, with the sequence repeated 
every 4 s for 24 h. Meals were quantified as described for CLAMS.  
 Hunger-induced feeding behavior. Mice were fasted for 9 hours during the light 
phase (with ad libitum access to water) before testing for evoked feeding behavior at the 
onset of feeding at the start of the dark phase. The primary photostimulation protocol 
consisted of 50 or 20 light pulses (10 ms each) which were delivered for 1 s (50 Hz or 20 
 68 
Hz, respectively), and the sequence repeated every 4 seconds for 12 hours. For the no 
starvation control, we used the average intake during the equivalent hours over 2 days. 
For meals analysis, food intake was binned over 5 min. A ‘meal’ was defined as any 
multiplicative of 5 min where the amount of intake the first 5 min was 10 mg or larger 
and no intake had been registered prior to that period. A meal was considered finished 
when no intake had been registered for another 10 min. 
Whole body composition analysis 
 Quantitative NMR to measure total fat and lean mass was done using EchoMRI. 
Animals were analyzed about three weeks after tamoxifen treatment.  
Electrophysiology 
 Whole-cell patch-clamp recordings were performed to assess the excitatory synaptic 
function in OGT KO PVN neurons. For this, we took advantage of αCaMKII-CreER+ x 
OGTFl/Wt x TdTFl mice. Acute PVN slices were prepared 17-19 days after tamoxifen 
injection at a similar time of day. Mice were anesthetized with isoflurane and decapitated. 
Brains were removed rapidly and placed in ice-cold cutting solution containing 210.3 
mM sucrose, 2.5 mM KCl, 1 mM NaH2PO4, 26.2 mM NaHCO3, 4 mM MgCl2, 0.5 mM 
CaCl2 and 11 mM D-(+)-glucose and oxygenated with 95% O2/5% CO2. Coronal slices 
(300 m thick) were cut with a vibratome (Leica VT1200S) and were kept in ACSF (125 
mM NaCl, 2.5 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 1.0 mM NaH2PO4, 26.2 mM 
NaHCO3 and 11 mM glucose, oxygenated with 95% O2/5% CO2) at 23–25 °C until 
recordings. Slices were placed in a submerged chamber and perfused with ACSF 
supplemented with 50 M picrotoxin and 1 M TTX. Targeted whole cell recordings of 
PVN tdTomato-positive neurons were made using pipettes of 2-5 M resistance. The 
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intracellular solution contained 115 mM CsMeSO4, 0.4 mM EGTA, 5.0 mM TEA-Cl, 1 
mM QX314, 2.8 mM NaCl, 20 mM HEPES, 3.0 mM MgATP, 0.5 mM GTP and 10 mM 
sodium phosphocreatine (pH = 7.2 and osmolality of 285–290 mOsm). Cells were held at 
-70mV holding potential and recording was performed at room temperature. The junction 
potential was left uncorrected. Signals were measured with a MultiClamp 700B amplifier 
and digitized using a Digidata 1440A analog-to-digital board (Molecular Devices). Data 
were acquired with pClamp 10 software and digitized at 20 kHz. Cell capacitance was 
measured. Miniature EPSCs (mEPSCs) were analyzed with MiniAnalysis (Synaptosoft) 
using a detection threshold of 7 pA (>2 times root mean square noise). Decay times were 
obtained by single-exponential fitting of the average mEPSC traces. 
Image analysis 
 Neuronal cell number. In vitro: Cell number was quantified by counting the number 
of DAPI stained primary cultured neurons. On each of three Wt and KO coverslips, 10 
random images were taken on a confocal microscope (Zeiss, LSM 510). In ImageJ, after 
setting a pre-defined threshold, the number of cells was counted automatically by 
applying the ‘Analyze particles’ command. In vivo: Cell number was quantified by 
counting the number of DAPI stained cells within the CA1 region of the hippocampus 
and the PVN in several slices from 3 Wt and 3 KO animals (confocal microscope, Zeiss, 
LSM 510). All slices were matched in distance from Bregma between Wt and KO. The 
number of cells was counted manually in the CA1 region. For the PVN, cells were 
counted automatically in ImageJ as described above. 
 Neuropeptide transcript expression. Within the PVN, the expression of the following 
probes was quantified: TRH, AVP, Oxytocin. Within the arcuate nucleus, the expression 
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of the following probes was quantified: POMC, CART, AgRP, NPY. In the lateral 
hypothalamus the expression of orexin was quantified. Images for quantification were 
taken on a Nikon Eclipse Ti, except for orexin where an Axiophot (Zeiss) was used. 
Images shown in Fig. 2.2 and 2.S7 were all taken on the Axiophot (Zeiss). Animals had 
been harvested in the early phase when KOs had just started to develop hyperphagia 
without developing any major obesity (about two weeks after tamoxifen treatment). 
Slices from the same 4 Wt and 4 KO animals were used for all probes, except for Wt 
CART where slices from 3 of the animals were used. Quantification was done in ImageJ. 
A pre-defined region of interest (ROI) was placed over each cell. The number of cells per 
image and the average intensity of each cell were collected. The right and left side of 
each brain region were imaged separately. Data were averaged per animal. Within the 
same probe, all sections were matched in distance from Bregma. The investigator was 
blinded to whether images came from Wt or KO animals during counting.  
 c-Fos and OGT expression in virus-injected PVN. Prior to harvest, CaMKII-
positive cells in the PVN had been labeled with virus expressing GFP under the 
CaMKII promoter by stereotaxic injection. Within the PVN, in ImageJ, all c-Fos 
positive cells per brain slice of the PVN were counted manually and marked as GFP-
positive or GFP-negative. All sections were matched in distance from Bregma. Note that 
the Wt virus GFP expression was higher than the KO virus GFP expression, a result we 
attributed to the combined GFP and Cre recombinase expression by the KO virus while 
the Wt virus expressed GFP alone. Therefore, for the GFP channel in KO slices, the 
microscope gain was set higher to include all GFP positive cells (confocal microscope, 
Zeiss, LSM 510).  
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 O-GlcNAc expression in organotypic slices and starved mice. All image analysis 
was done on raw, unmanipulated images in ImageJ. Cells and background were marked 
with a pre-defined ROI. For TdT/GFP positive cells, the ROI was placed over positive 
cells in the TdT/GFP channel. For TdT/GFP negative cells, cells were picked randomly 
in the DAPI channel and then verified as TdT/GFP negative in the TdT/GFP channel. If 
the ROI marked a TdT/GFP positive cell, the ROI was moved to a cell nearby. The 
background in each image was quantified by measuring the average intensity of three 
ROIs placed over cell-empty areas as judged by no DAPI signal. After placing all ROIs, 
the mean intensity was measured in the O-GlcNAc channel. The background value was 
subtracted from each cell value. The experimenter was blinded to the O-GlcNAc channel 
when placing the ROIs.  
 Image presentation. All image analysis was done on raw, unmanipulated images. For 
presentation purposes, most shown immunohistochemistry images and DAPI stained 
images were improved post hoc. All manipulations were applied equally within the same 
experiment and to Wt and KO images. The manipulations (done in Photoshop) were the 
following: change of Levels and Brightness/Contrast and Filtering (‘Despeckle’ and 
‘Gaussian blur’ (2.0pixels)). 
Statistical analysis 
 Statistical analyses were done using the program Prism 5. Repeated-measures two-
way analysis of variance (ANOVA) analyses detected significant interaction of ‘time’ 
and ‘genotype’, and post hoc Bonferroni analyses detected statistical significance 
between individual time points. In Fig. 2.S3A, one-way ANOVA was applied to calculate 
significant interaction between all groups and then the difference between all separate 
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group combinations was tested post hoc with Tukey’s Multiple Comparison Test. For in 
situ hybridization, statistical analysis compared between animals mean data averaged 
over all imaged slices. All Student’s t-tests were two-tailed and unpaired. Star, ‘*’, 
signifies P<0.05. All error bars represent mean +/- standard error of the mean (s.e.m.). A 
few animals where either some food intake or body weight value had been missed were 
omitted in repeated-measures two-way ANOVA analyses and post-hoc Bonferroni 
analyses. However, these values did not change the overall result and were included in 
shown graphs. The normality distribution of data used for the F-test in Fig. 2.S6C was 



















Most content (e.g. text, figures and experimental results) included here is modified from 
work that will be submitted for publication: 
1. Lagerlöf O, Hart GW, Huganir RL. OGT regulates excitatory synapse maturity. In 
preparation.  
3.1 Abstract 
Experience-driven synaptic plasticity is believed to underlie adaptive behavior by 
rearranging the way neuronal circuits process information. We have previously 
discovered that O-GlcNAc transferase (OGT), an enzyme that modifies protein function 
by attaching -N-acetylglucosamine (GlcNAc) to serine and threonine residues of 
intracellular proteins (O-GlcNAc), regulates food intake through mediating excitatory 
synaptic function. However, how OGT affects excitatory synapse function is largely 
unknown. Here we demonstrate that OGT is enriched in the postsynaptic density of 
excitatory synapses. In the postsynaptic density, O-GlcNAcylation on multiple proteins 
increased upon neuronal stimulation. Removal of OGT decreased the synaptic expression 
of the GluA2 and GluA3, but not the GluA1, subunits of the AMPA receptor. The 
number of opposed excitatory presynaptic terminals was sharply reduced upon 
postsynaptic knock out of OGT. There were also fewer dendritic spines on OGT knock 
out neurons and those that were present had not developed morphology akin to mature 





Neuronal synapses, the cell-cell junctions over which neurons communicate, are formed 
and eliminated throughout life and their turnover has for decades been associated with the 
way neuronal circuits adapt to environmental challenges to optimize behavior (111, 112). 
In both humans and animals, early development is characterized by massive generation of 
new synapses. About half of all synapses are then lost during adolescence (112, 113). 
Most mature excitatory synapses occur on dendritic protrusions called spines and 
essentially all spines contain an excitatory synapse (114-116). In vivo imaging of 
individual spines for days to months has shown that adult spines are largely stable but a 
small subpopulation remains plastic (113, 117) and spine turnover is increased by novel 
experience (115, 118-120). While most new spines are thin and withdraw rapidly, some 
enlarge and form stable synaptic contacts (112, 113, 117, 121-124). In fact, the 
stabilization of a subset of new spines correlates with behavioral performance in several 
different tasks in multiple animal species (123, 125-127). Rather than synapse formation 
or density, the selection of which spines are retained once formed has been suggested to 
match circuit architecture with behavioral needs (128). Without affecting spine 
formation, deleting -adducin, which regulates actin, perturbed the process by which 
nascent spines establish functional synapses and impaired long-term memory (129). 
Fragile X Syndrome, a common form of mental retardation, exhibits a higher than normal 
density of spines but more of them exhibit an immature morphology and their turnover is 
not affected by sensory experience (119, 130). Conversely, the protein Telencaphalin 
arrests the maturation of spines and its removal enhances several forms of learning (123, 
131).  
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The association between learning and spine survival suggests that synaptic 
maturation is regulated by neuronal activity (112). Long-term synaptic potentiation (LTP) 
caused by repeated stimulation of excitatory synapses, a predominate model for encoding 
of learning and memory on a cellular level, protects activated spines from removal (132, 
133). Likewise, Hill and Zito induced LTP specifically on individual newly formed 
spines through glutamate uncaging and observed potent stabilization (134). While also 
causing some spines to be eliminated, LTP does not consistently lead to a lasting increase 
in overall spine density (114, 132, 135, 136). It is widely believed that LTP is caused by 
insertion of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors 
into the synaptic cleft. AMPA receptors are glutamate-gated tetrameric ion channels 
composed of different combinations of subunits GluA1-4 and conduct the majority of the 
fast excitatory neurotransmission in the brain (103). AMPA receptors may not be 
obligatory for spine formation in early development, as knocking out (KO) GluA1-3 
shortly after birth did not change spine density (137). However, knocking down GluA1-3 
increases the number of inactive presynaptic terminals and overexpression of the GluA2 
as well as the GluA4 subunits recruits synapses (138-140). Nascent spines incorporate 
AMPA receptors within a few tens of minutes of formation and so-called 'silent spines', 
where AMPA receptors cannot be detected, do not correspond to the age of the spine but 
only its size (123, 141-144). Live imaging has shown that the frequency of local 
postsynaptic calcium transients within seconds to minutes upon contact between a 
dendritic protrusion and an axon correlates with the retention of that contact (122). While 
blocking glutamate signaling did not affect these early events, it did arrest subsequent 
molecular organization of the spine, including decreasing its long-term stability (122, 
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124, 133). AMPA receptor stimulation, rather than overall neuronal activity, can rescue 
the loss of spines that occurs upon removal of presynaptic inputs (111, 145). Similar to 
LTP, which occurs mainly at small spines, inhibiting AMPA receptor signaling decreases 
spine density by reducing the number of small and thin spines (114, 146-148). Long-term 
depression (LTD) of excitatory synapses involves synaptic removal of AMPA receptors 
and leads to fewer and smaller spines (114, 149). A downstream target of AMPA 
receptor-dependent regulation of spine maturation is actin, e.g. via modulation of the 
RhoA signaling cascade (148, 150).  
Synapse formation and termination are multi-step processes where the stability, or 
maturity, of the spine is continuously surveyed by activity-dependent processes. Though 
many molecules that affect synapse number have been identified over the last decade, it 
is still unclear how these are regulated to refine information processing to optimize 
behavior (162). In neurons, the O-GlcNAc pathway has emerged recently as critical for 
coupling cellular function to metabolic hormones and to energy availability through 
nutrient-dependent flux via the hexosamine biosynthesis pathway (HBP), which produces 
UDP-GlcNAc, the donor substrate for OGT (Lagerlöf et al. (2016), Science. In press; (2, 
179, 182)). Unlike complex glycans present on the outside of cells and in the secretory 
pathway, O-GlcNAc is a highly dynamic sugar that is added and removed repeatedly over 
the lifespan of a single peptide chain. It is expressed mainly on the inside of cells in the 
nucleus and cytoplasm. Only two enzymes regulate its cycling; O-GlcNAc transferase 
(OGT) attaches O-GlcNAc to proteins covalently, whereas O-GlcNAcase (OGA) 
hydrolyses O-GlcNAc from proteins. Brain is one of the organs where O-GlcNAc is the 
most abundant (2, 5). In the synapse, a myriad of proteins carry O-GlcNAc (3, 68, 69). 
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Many of these are critical for synaptic plasticity like CaMKII and SynGAP (3, 193). O-
GlcNAc signaling does affect learning and memory (8, 194). Acute inhibition of OGT or 
OGA pharmacologically indicated that O-GlcNAc regulates LTP and LTD by affecting 
AMPA receptor trafficking. However, there have been contradictory reports whether 
global elevation or depression of O-GlcNAc levels have a stimulatory or inhibitory 
effect, respectively, on excitatory synaptic function, possibly due to unspecific 
pharmacology against OGT or differences in mode and length of application of drugs 
against OGA (7, 104, 194). We developed a new mouse model where OGT was deleted 
genetically from mature brain neurons in vivo and demonstrated that OGT regulates 
normal food intake, at least in part, by mediating excitatory synaptic function (Lagerlöf et 
al. (2016), Science. In press). Using electrophysiology, we observed that knocking out 
OGT sharply reduced the frequency of miniature excitatory postsynaptic currents 
(mEPSCs). mEPSC amplitude was also decreased, but to a lesser degree. These findings 
indicate that OGT underlies adaptive behavior partly by mediating normal excitatory 
synaptic function (Lagerlöf et al. (2016), Science. In press).  
Here we investigate how OGT regulates excitatory synaptic function by taking 
advantage of primary neuronal cell culture where OGT is deleted genetically either 
systemically or in sparse neurons. We discovered that OGT deletion greatly reduced the 
synaptic expression of GluA2/3 heteromers, a major AMPA receptor isoform. Mimicking 
our electrophysiological finding of lower mEPSC frequency in vivo, removal of OGT in 
vitro led to fewer mature morphological synapses and fewer dendritic spines. The spines 
that were present on OGT KO neurons were largely immature. Collectively, our 
observations suggest that OGT is important for the maturation of excitatory synapses, at 
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least in part through modulating GluA2/3 expression. The regulation of synapse maturity 
by OGT represents a new model for how neuronal circuits may respond to environmental 
challenges, such as nutrient fluctuations, to accommodate behavior.  
3.3 Results 
3.3.1 OGT is enriched in the postsynaptic density of excitatory synapses 
Based on biochemical fractionation, it has been shown previously that OGT is present in 
neuronal synapses (7, 68). Electron microscopy from the cerebellum indicated that OGT 
is more highly expressed in presynaptic, rather than postsynaptic, nerve terminals (69). 
To investigate the role of OGT in postsynaptic function, we applied a fractionation 
protocol to forebrain homogenate that allowed purification of the postsynaptic density 
(PSD) of excitatory synapses. Equal amounts of all fractions were separated by SDS-
PAGE and analyzed by Western blotting. Enrichment of the PSD marker PSD-95 and 
exclusion of the presynaptic marker synaptophysin ensured that the PSD fraction isolated 
PSDs specifically (Fig. 3.1A). OGT was present in all subcellular compartments, 
including in the PSD (Fig. 3.1A). Interestingly, compared to the whole-cell homogenate, 
OGT was more than twice as abundant in the PSD (Fig. 3.1B). In contrast to OGT, OGA 
was less abundant in the PSD (Fig. 3.1A). We then used immunohistochemistry to 
examine the localization of OGT in primary cultured hippocampal neurons. Along the 
dendrite, OGT expression was punctate and many, but not all, puncta overlapped with 
PSD-95 (Fig. 3.1C). Introducing a C-terminal truncation of OGT (dCTD), removing a 
region that has been associated with OGT's interaction with the plasma membrane (48), 
largely abolished OGT's postsynaptic expression (Fig. 3.1D). This effect did not depend 
on different expression levels between wildtype (Wt) and mutant OGT as dCTD-OGT 
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was confined to the soma regardless of amount of DNA used for transfection (Fig. 3.1D). 
In addition, the somatic expression between Wt OGT and dCTD-OGT did not differ (Fig. 
3.1D). It has been shown that depolarization of cultured neuroblastoma cells using KCl 
activates OGT via calcium-dependent phosphorylation by CaMKIV (56). Moreover, 
induced seizures in rodents increased the O-GlcNAcylation of some proteins in the brain 
in vivo (71). However, whether, and to what extent, neuronal firing regulates O-GlcNAc 
incorporation in neurons is still unclear. Taking advantage of two-dimensional gel 
electrophoresis and blotting for O-GlcNAc, we observed that stimulating neuronal 
network activity in cortical cultures by inhibiting GABAA receptors pharmacologically 
(bicuculline) elevated O-GlcNAcylation in the PSD on multiple proteins (Fig. 3.1E). 
Together, our observations demonstrate that OGT is enriched in the PSD of excitatory 
synapses in forebrain neurons, where its localization relied upon its CTD. Within the 
PSD, O-GlcNAcylation is a dynamic and activity-dependent posttranslational 
modification. 
3.3.2 OGT regulates the synaptic expression of AMPA receptors 
Recently, we knocked out OGT in adult animals and observed a marked attenuation of 
excitatory synaptic currents using electrophysiology (Lagerlöf et al. (2016), Science. In 
press). Other groups have shown that acute inhibition of OGT or OGA activity affects 
LTP and LTD in the CA1 region of the hippocampus, possibly through altered AMPA 
receptor trafficking (7, 104, 194). Two major AMPA receptor isoforms are GluA1/2 and 
GluA2/3 heteromers (103, 195). Here we deleted OGT in cortical neurons cultured from 
floxed OGT mice (OGTFl) by applying lentivirus expressing either GFP alone (Wt) or 
GFP together with Cre recombinase (KO) at DIV2. After the neurons had matured, we 
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precipitated the surface protein population using biotinylation and blotted for the major 
AMPA receptor subunits. As shown in Fig. 3.2A, only proteins expressed on the surface 
of the cell were pulled down applying this method. There was no change in the total 
expression of PSD-95 upon deleting OGT (Fig. 3.2A-B). In contrast, removal of OGT 
caused a sharp downregulation of the surface expression of the GluA2 and the GluA3 
AMPA receptor subunits but not the GluA1 subunit (Fig. 3.2A, C). Also the total 
expression of GluA2 and GluA3 was decreased (Fig. 3.2A-B). There was no effect on the 
relative surface over total expression of either subunit, albeit there was a trend towards a 
small decrease for GluA1 (P=0.05, n=6 for Wt and KO, Fig. 3.2D). We also isolated the 
PSD from OGT Wt and KO cultures. In the PSD, there was a reduction in GluA3 while 
there was an increase in GluA1 (Fig. 3.2E-F). GluA2, again, was expressed at a level 
between GluA1 and GluA3 (9% decrease, P=0.08, Fig. 3.2E-F). Next, we sparsely KO 
OGT in hippocampal cultures from OGTFl mice by transfecting a cell-fill (GFP) and an 
empty plasmid (Wt) or a plasmid expressing Cre (KO) around DIV9. At DIV14 we used 
immunohistochemistry to stain the surface GluA2 population using an antibody directed 
against its N-terminus and, after permeabilization, the total GluA2/3 population with a C-
terminus-targeted antibody. There was no overt difference in the overall morphology 
between Wt and KO neurons (Fig. 3.3A). In the soma, the total GluA2/3 expression did 
not change upon OGT KO (Fig. 3.3B). In contrast, along dendrites, similar to what we 
showed biochemically, the number of surface GluA2 positive puncta decreased by 51% 
(P<0.05, Wt n=27, 4.9 ± 0.5; KO n=28, 2.4 ± 0.2, Fig. 3.3C-D). Likewise, the number of 
total GluA2/3 puncta was 51% lower in OGT KO neurons (P<0.05, Wt n=27, 5.4 ± 1.1, 
KO n=28, 2.7 ± 0.69, Fig. 3.3C, E). This change in expression was not reflected in the 
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size of the surface GluA2 puncta and the size of the GluA2/3 puncta was only slightly 
smaller (Fig. 3.3C, F-G). Using biochemistry and imaging, our results indicate that OGT 
is necessary cell-autonomously for normal synaptic expression of AMPA receptors, in 
particular the GluA2/3 heteromer.  
3.3.3 Postsynaptic deletion of OGT leads to fewer presynaptic terminals 
As deletion of OGT mainly affected the number of GluA2 puncta along dendrites rather 
than the somatic expression of GluA2/3 or the expression of surface GluA2 per punctum, 
we reasoned that OGT may regulate the number of synaptic contacts. This idea would be 
consistent with our previous electrophysiological data showing that OGT removal 
primarily leads to lower mEPSC frequency (Lagerlöf et al. (2016), Science. In press). 
After sparsely labeling and deleting OGT in hippocampal cultures as described above, 
immunohistochemistry was applied to stain for vGlut1, a marker for excitatory 
presynaptic terminals, and PSD-95 (Fig. 3.4A). The number of puncta and the size of 
each punctum overlapping with the cell-fill was then quantified. There was no significant 
change in the number or the size of PSD-95 positive puncta (Fig. 3.4A-C). In contrast, 
there was a 47% drop in the number of vGlut1 puncta (P<0.05; Wt n=21, 2.7 ± 0.4 
puncta/10m; KO n=18, 1.4 ± 0.3 puncta/10m, Fig. 3.4A, D). The size of the vGlut1 
puncta did not differ between Wt and KOs (Fig. 3.4E). Together, our data suggest that the 
formation of postsynaptic structures, as determined by PSD-95, is not affected by 
removing OGT. In contrast, deleting OGT in the postsynaptic cell prevents the 
specialization of opposing presynaptic terminals. These observations corroborate and 
expand the previous finding that the drop in mEPSC frequency upon OGT KO in vivo 
reflects a loss of functional synapses (Lagerlöf et al. (2016), Science. In press).  
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3.3.4 OGT removal is associated with deficient spine maturation 
Most excitatory synapses occur on dendritic spines (112). Filling the neuron with a 
fluorescent marker, spines can be imaged and their number and shape measured. Whereas 
the number of spines is a function of the number of excitatory synapses, the shape of the 
spine indicates its maturity (114-116). Mature and stable spines typically exhibit a wider 
distal portion ('spine head') (Fig. 3.5a) (112, 113, 121-124, 132). Here, again, 
hippocampal cultures from OGTFl mice were sparsely transfected to label cells and KO 
OGT at DIV9 and then fixed at DIV14. Upon deletion of OGT, spine number decreased 
by 43% (P<0.05; Wt n=26, 3.9 ± 0,3 spines/10m; KO n=28, 2.2 ± 0.2 spines/10m, Fig. 
3.5A-B). Spine shape was measured by quantifying the ratio between the width and the 
length of individual spines (Fig. 3.5A). Counting all spines, deleting OGT decreased their 
mean shape ratio by 33% (P<0.05, Wt n=1108, 0.85 ± 0.02, KO n=1074, 0.57 ± 0.01, 
Fig. 3.5C). To evaluate the proportion of mature versus immature spines, spines with a 
ratio above 0.5 were labeled 'mature' and those with a ratio below 0.5 'thin' (Fig. 3.5A). In 
Wt cells, the majority of all spines were mature (Fig. 3.5D). Of those spines that were 
present on OGT KO cells, in contrast, most were thin (Fig. 3.5D). To summarize, 
deleting OGT leads to a higher proportion of immature spines and fewer spines in total 
(Fig. 3.5E).  
3.4 Discussion 
Neuronal circuits need to constantly rearrange their connectivity pattern in order to match 
behavioral output to environmental influences. Here we find that OGT, a nutrient-
dependent enzyme, is enriched in the postsynaptic density of excitatory synapses. In the 
PSD, the abundance of O-GlcNAc was dynamic and dependent on neuronal activation. 
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Deletion of OGT greatly depressed the synaptic expression of the GluA2 and GluA3 
subunits of the AMPA receptor. The reduction in GluA2 and GluA3 expression was 
largely due to fewer dendritic AMPA receptor clusters rather than a decrease in the 
amount of AMPA receptors in each cluster, indicating that the main effect of OGT 
removal would be explained by a downregulation of the number of functional excitatory 
synapses. Indeed, removing OGT postsynaptically disrupted the formation of opposing 
presynaptic terminals, as determined by staining of the synaptic vesicle protein vGlut1. 
There were also fewer spines on OGT KO neurons. Those spines that did form were 
mostly immature and did not express morphological features reminiscent of stable 
synapses. In contrast, the total expression of PSD-95 was not affected upon OGT KO, 
and neither was the density of PSD-95 puncta along dendrites or their size.  
Total spine number is regulated by the formation of new spines and the 
termination of old spines. We deleted OGT genetically before or during the period of the 
most extensive synapse formation in culture (DIV7-14) and observed a marked reduction 
in spine density. Accordingly, albeit we have not applied methods such as live imaging of 
individual spine turnover to verify this idea, it is likely that the decrease in total spine 
number upon OGT KO mainly resulted from disrupted spine formation. However, 
deleting OGT did not affect the expression and clustering of PSD-95, which is an integral 
protein of the PSD (133). At many synapses, PSD-95 clustering precedes the 
accumulation of presynaptic components such as synaptic vesicles (112, 129, 196, 197). 
In the PSD of OGT KO cells, there was a comparatively high abundance of GluA1-
containing receptors while GluA3-containing receptors were lower in abundance than in 
Wt cells. Similarly, on the cell surface, there was a reduction in GluA2 and GluA3 but 
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not GluA1. As GluA2 consistently expressed at levels between GluA1 and GluA3 upon 
removal of OGT, the main effect of deleting OGT presumably occurs on GluA2/3 
heteromers as opposed to on GluA1/2 heteromers. Early in development, GluA4 
translocates into so-called silent synapses and are later replaced by GluA2-containing 
receptors (198-200). While synaptic insertion of GluA1 homomers and GluA1/2 
heteromers require neuronal stimulation, GluA2/3-heteromers can be inserted under 
baseline conditions in exchange for pre-existing receptors (201, 202). However, unlike 
GluA1, GluA2 does not appear to enter into silent synapses (201). Sensory experience 
and learning increase the abundance of GluA1 homomers in the synapse, but this increase 
is often transient (160, 161, 202). Although the trafficking of GluA2/3 can be regulated 
by neuronal activity, these and other data suggest that GluA2/3 heteromers, as opposed to 
GluA1 homomers or GluA1/2 heteromers, are associated with the maintenance of 
synaptic strength in mature synapses (103, 159). Whereas total spine number was 
reduced, spines did develop on OGT KO cells. But of those spines that formed, most 
resembled immature spines and rarely evolved morphology akin to mature spines with a 
wider spine head as in Wt cells. Spine formation is intimately linked to synapse 
formation (112, 113, 121-124). The formation of presynaptic terminals on dendrites 
where OGT had been deleted, as determined by overlapping staining of the synaptic 
vesicle protein vGlut1, was interrupted. Based on the selective effect on GluA2/3 
heteromers, immature spine phenotype and reduction in the number of vGlut1 puncta but 
not PSD-95 puncta, it appears that OGT is necessary for later, rather than early, stages of 
postsynaptic development when otherwise unstable spines mature into functional 
synapses (Fig. 3.5E).  
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Although the experiments presented in this paper were performed in the context 
of synapse formation in culture, previously we have observed a similar decrease in 
excitatory synapse number in adult animals. After OGT was removed acutely in vivo, 
there was a sharp drop in mEPSC frequency (Lagerlöf et al. (2016), Science. In press). In 
addition, other groups have shown that short-term nutritional or pharmacological 
manipulation of global O-GlcNAc levels in hippocampal slices affects long-term 
potentiation and long-term depression of excitatory CA1 synapses (7, 104, 194). At least 
some of these effects were related to altered trafficking of GluA2 (104, 194). 
Collectively, these observations suggest that OGT is important not only for the formation 
of new excitatory synapses during development but also for the stability of excitatory 
synapses in the adult. As discussed above, spines undergo constant remodeling where 
activity-dependent signaling through AMPA receptors, e.g. via actin, maintain their 
stability. Thus, it is possible that the synaptic depression of GluA2/3 heteromers upon 
OGT deletion prevented the development of thin spines into mature synapses. The idea 
that OGT underlies spine maturity via maintaining AMPA receptor expression would 
explain why removing OGT during development and in adult animals lead to the same 
phenotype; loss of excitatory synapse number.  
OGT may regulate AMPA receptor expression through several pathways. We 
show here that the O-GlcNAc content in the PSD is dynamic. We also observed that OGT 
is enriched in the PSD and that its postsynaptic expression relies on the CTD of OGT, a 
region that has been associated with membrane translocation of OGT (48). Global and 
long-term deletion of OGT decreased the total expression of GluA2 and 3. In contrast, 
shorter and sparse OGT KO did not affect the somatic expression of GluA2/3. This 
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indicates that OGT regulates AMPA receptor expression by a cell-autonomous 
mechanism, probably, at least in part, through degradation or trafficking of the receptor, 
which is supported by the fact that the effect of acute manipulation of global O-GlcNAc 
levels on excitatory neurotransmission is GluA2-dependent (194). Moreover, we and 
others have shown that O-GlcNAc regulates excitatory synapse function in hypothalamic, 
cortical and hippocampal cells. Thus, the manipulation of synaptic AMPA receptor 
abundance may be a common and major endpoint for how OGT shapes neuronal circuits. 
Many O-GlcNAc-modified proteins known to affect AMPA receptor trafficking have 
been identified using mass spectrometry, e.g. SynGAP and CaMKII (3, 193). Based on 
these observations, it is likely that OGT may regulate AMPA receptor expression via 
pathways local to the spine or the postsynaptic density, but other mechanisms cannot be 
excluded.  
O-GlcNAc is increasingly being appreciated as an important modification of 
protein function. Its unique regulation where metabolic and other stimuli can affect O-
GlcNAcylation on a global as well as a target-specific scale presents a novel mechanism 
for how cells respond to environmental challenges. Here we demonstrate that OGT is 
enriched in the postsynaptic density of excitatory synapses and is necessary for synapse 
maturation, possibly via regulating the synaptic expression and/or localization of 
GluA2/3 heteromers. O-GlcNAc cycling in the brain is linked to learning and memory, 
feeding behavior and neurodegenerative diseases (2, 8, 194). While many proteins in the 
excitatory postsynapse are known to be modified by O-GlcNAc, an important task will be 








Fig. 3.1. OGT is enriched in the postsynaptic density of excitatory synapses. (A) Wb 
of PSD preparation fractions from brain. (B) Quantification of OGT expression in the 
PSD relative to the whole-cell fraction (n=7 for Hom. and PSD; two-tailed t-test: 
P<0.05). (C) Immunohistochemistry of OGT (green), PSD-95 (magenta) and MAP2 
(gray). Right image shows boxed area from left image in higher magnification. (D) Left: 
Expression of GFP and different HA-tagged OGT constructs in cultured hippocampal 
neurons. Binary images are shown. Right: quantification of OGT expression (HA) in the 
soma of transfected neurons (Full-length n=13, dSPY n=8; two-tailed t-test: P<0.05). (E) 
Wb of two-dimensional gel electrophoresis of the PSD fraction from control and 









Fig. 3.2. OGT regulates the synaptic expression of AMPA receptors. (A) Wb of the 
total and surface expression of GluA1-3. (B) Quantifications of the total expression from 
(A) (GluA1-3: n=5 for Wt and KO; PSD-95: n=3 for Wt and KO; two-tailed t-test: 
P<0.05). (C) Quantifications of the surface expression from (A) (GluA1-3: n=6 for Wt 
and KO; two-tailed t-test: P<0.05). (D) Quantifications of the surface over total 
expression from (A) (GluA1-3: n=6 for Wt and KO; two-tailed t-test: P<0.05). (E) Wb of 
PSD preparation fractions from Wt and KO cells. (F) Quantification of GluA1-3 
expression in the PSD (n=3 for Wt and KO; two-tailed t-test: P<0.05). Quantifications 








Fig. 3.3. Deletion of OGT leads to fewer surface GluA2 clusters. (A) Thresholded 
images of GFP expression in Wt and KO hippocampal neurons. (B) Quantification of the 
total expression of GluA2/3 in the cell soma of individual hippocampal neurons (Wt 
n=18, KO n=20; two-tailed t-test: P<0.05). (C) Immunohistochemistry of the surface 
expression of GluA2 and total expression of GluA2/3 in dendrites from transfected 
neurons. The outlines of the cell (GFP expression) are shown in yellow. (D-G) 
Quantifications from (C) (Wt n=27, KO n=28, two-tailed t-test: P<0.05). Quantifications 













Fig. 3.4. OGT regulates the number of mature synaptic contacts. (A) 
Immunohistochemistry of vGlut1 and PSD-95 overlapping with transfected neurons. The 
outlines of the cell (GFP expression) are shown in yellow. (B-E) Quantifications from 
(Wt n=21, KO n=18, except for vGlut puncta size where n=16, two-tailed t-test: P<0.05). 













Fig. 3.5. Fewer and more immature spines on OGT KO neurons. (A) Left: 
Expression of GFP in dendrites from Wt and KO hippocampal neurons. Right: Schematic 
of measurements taken to quantify spine shape. (B) Quantification of spine density (Wt 
n=26, KO n=28, two-tailed t-test: P<0.05). (C) Quantification of the mean spine shape 
ratio (Wt n=1108, KO n=1074, two-tailed t-test: P<0.05. (D) Quantification of the 
proportion of mature and thin spines along dendrites. (Wt n=27, KO n=28, two-tailed t-
test: P<0.05). (E) Model of how OGT, at least in part, regulates excitatory synapse 
function; OGT inhibits the maturation of dendritic spines leading to fewer and more 
immature synapses. Quantifications represent mean ± s.e.m. 
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3.5 Materials and Methods 
Materials. Mice where an exon in the Ogt locus has been floxed (OGTFl) to delete OGT 
has been described previously (Lagerlöf et al. (2016), Science. In press; (6). Antibodies 
used were: OGT (AL25 and AL28, produced in-house, 1:5000), O-GlcNAc (110.6, 
produced in-house, 1:10000), OGA (345, produced in-house, 1:5000), HSP70 (Santa 
Cruz Biotechnology, 1:1000-5000), PSD-95 (NeuroMab, Wb; 1:5000, IF; 1:2000), 
GluA1 (4.9D, produced in-house, 1:10000), GluA2 (Wb; Mab, produced in-house, 
1:5000, IF; 15F1, a kind gift from Dr Eric Gouaux, 1:500-1000), GluA3 (JH4300, 
produced in-house, 1:5000), GluA2/3 (JH4854, produced in-house, 1:250), MAP2 
(nb300-213, Novus biologicals, 1:10000), Synaptophysin (SVP-38, Sigma, 1:10000), HA 
(12CA5, 1:200), vGlut1 (AB5905, Millipore, 1:2500), GFP (ab13970, Abcam, 1:2500). 
All plasmid inserts used had been generated by standard cloning techniques previously 
in-house. All animals were housed according to the Johns Hopkins University Animal 
Care and Use Committee guidelines. 
 Primary neuronal cell culture. For biochemistry, rat and mice E18 cortical neurons 
were prepared as previously described (Lagerlöf et al. (2016), Science. In press). Briefly, 
after dissociation, cells were plated on poly-L-lysine coated dishes in neuronal growth 
media with 5% serum, NM5 (Neurobasal growth medium (GIBCO), 2% B27 
(Invitrogen), 2 mM Glutamax (GIBCO), 5% Fetal Bovine Serum and PenStrep 
(GIBCO)). Dividing cells were removed using 5 mM uridine and 5 mM (+)-5-fluor-2’-
deoxyuridine in NM1 (1% serum) at days in vitro (DIV) 3-5). Then, every 3-4 days, half 
of the culture media was exchanged for glia-conditioned NM1 until harvest. For OGT 
KO experiments, lentivirus was added on DIV 2. SDS-PAGE and Western blotting were 
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done according to standard procedures. For imaging, mice E16.5-17 and rat E18 
hippocampal neurons were cultured in serum-free media (NM0). Upon transfection, half 
of the media was exchanged for fresh NM0. Transfections were done using Lipofectamin 
2000 (Fisher).  
 Imaging. Mature hippocampal neurons were fixed with 4% paraformaldehyde and 
4% sucrose. When surface staining was performed, the fix was applied for 4.5 min in 
room temp, which did not break the cell membrane. Thereafter, the GluA2 antibody 
raised against the N-terminus of GluA2 was applied in room temp for 2 h in a blocking 
buffer (0.1% gelatin, 250 mM NaCl, 15 mM phosphate buffer, pH7.4) that did not 
contain any detergent. After washing, other primary antibodies were introduced in 
blocking buffer that did contain detergent (0.25 % Tx-100) for 2 h at room temp. 
Secondary antibodies, diluted in blocking buffer plus 0.25% triton, were added for 1 h 
after washing. For other staining, the neurons were fixed using the same solution but for 
15 min at 4C, permeabilized for 10 min at 4C (0.25% Tx-100 in PBS) and blocked for 
at least 1 h (5-10% normal goat serum in PBS). All antibodies were diluted in the same 
blocking buffer and applied for 1-2 h. 
 Lentivirus. To KO OGT in cultured neurons, pseudotyped VSV-G lentivirus 
expressing GFP alone (Wt) or GFP together with Cre recombinase (KO) was produced 
according to standard procedures (Lagerlöf et al. (2016), Science. In press).  
 PSD isolation. From neuronal culture: Cells were harvested and homogenized in 
homogenization buffer (0.32 M sucrose, 4mM HEPES pH7.4, including inhibitors for 
proteases, phosphatases and O-GlcNAcases). After homogenization, in all subsequent 
steps including adding any solution, the same inhibitors as used for the homogenization 
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buffer were added. The homogenate (H) was centrifuged (1000xg, 10 min, 4C). The 
supernatant was spun again (10000xg, 15 min, 4C). The pellet was resuspended in 
homogenization buffer and spun again (10000xg, 15 min, 4C). The pellet was lyzed by 
hypo-osmotic shock in H2O (P1000 pipet x 20-30 times) and then adjusted to 4 mM 
HEPES, pH7.4. This fraction was used as P2. The remained material was rotated at 4C 
for 30 min before ultracentrifugation (25000xg, 20 min 4C). The pellet was resuspended 
in 50 mM HEPES, pH 7.4, e mM EDTA). After 0.5% Triton X100 had been added, the 
solution was rotated at 4C for 15 min and then centrifuged again (32000xg, 20 min, 4C) 
to yield the PSD fraction. From brain (the cerebellum and most of the midbrain and 
brainstem were removed): the tissue was homogenized (fraction H, 0.32 M sucrose, 10 
mM HEPES, pH 7.4, including inhibitors for proteases, phosphatases and O-
GlcNAcases) and then centrifuged (1000xg, 10 min, 4C) to yield the P1 fraction. After 
homogenization, in all subsequent steps including adding any solution, the same 
inhibitors as used for the homogenization buffer were added. The supernatant (S1) was 
spun again (13800xg, 20 min, 4C) where the supernatant was collected as S2. The pellet 
(P2) was resuspended in homogenization buffer and layered on a sucrose gradient (P2 - 
0.85 M - 1.0 M - 1.2 M sucrose in 1mM HEPES, pH 7.4) and centrifuged (82500xg, 2 h, 
4C). The material between the 1.0 M and 1.2 M layers  was collected and diluted with 
2.5 volumes of 10 mM HEPES, pH 7.4 before centrifugation (150000xg, 30 min, 4C). 
The pellet (SPM) was resuspended in 80 mM Tris-HCl, pH 8.0, and then diluted with 
1.0% Triton X100 to a final concentration of 0.5% Triton X100. The solution was rotated 
for 15 min (4C) and then centrifuged (32000xg, 20 min, 4C) to yield the PSD fraction 
(the pellet).  
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 Surface biotinylation. Cells were washed 2-3 times in aCSF (143 mM NaCl, 5 mM 
KCl, 2 mM CaCl2 1 mM MgCl2, 10 mM HEPES pH 7.4, 10 mM D-glucose) and then 
incubated on ice fro 20 min in Sulfo-NHS-SS-Biotin (Fisher) diluted in aCSF. Remaining 
active biotin was quenced with TBS three times (4C, 5 min each wash) and then lyzed in 
RIPA buffer (50mM tris, 150mM sodium chloride, 1% NP-40, 1% deoxycholate, 0.1% 
SDS, 1mM EDTA, including inhibitors for proteases, phosphatases and O-GlcNAcases). 
Biotinylated proteins were pulled down using neutravidin beads (Fisher).  
 Isoelectrofocusing. Two-dimensional electrophoresis was done according to 
standard procedures (57). Briefly, from mature neuronal cell cultures (DIV14-20) treated 
with vehicle or bicuculline (40 M) for 5 h, the PSD fraction was isolated and 
resuspended in 7 M urea, 2 M thiourea, 2% dodecyl maltoside (D4641, Sigma), 50 mM 
DTT, 0.2% ampholytes (BioLyte 3–10 IEF buffer from Bio-Rad) and inhibitors for 
proteases, phosphatases and O-GlcNAcases. The sample was then swelled overnight at 
room temperature onto Readystrip IPG Strips (pI 3–10) (Bio-Rad), isoelectrofocused and 
treated with DTT and iodoacetamide before separated using SDS-PAGE. Subsequent 
Western blotting was done according to standard procedures. 
 Image quantification and presentation. All analysis was done on non-
manipulated, raw images in ImageJ. For quantification of puncta number and size, the 
cell-fill channel (GFP) was thresholded and then used to create a mask tracing the border 
of the cell. Only secondary and tertiary dendrites were included, and their total length 
measured per image. Then the channel for each type of punctum was thresholded and 
counted within the cell-fill mask using the 'analyze particles' function. The number and 
size of each punctum was recorded. The number of puncta was divided by the length of 
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the corresponding dendrite, and both spine density and spine shape were quantified per 
image. Spines were counted manually. Only secondary and tertiary dendrites were 
included, and their total length measured per image. The total spine number was divided 
by the length of the corresponding dendrite per image. The length between the tip of each 
spine and the junction between the spine and the dendrite and the width of the head of 
each spine were measured manually on 50 randomly picked spines per image. The shape 
of each spine was calculated by dividing the width by the length of each spine. This ratio 
was compared between all Wt and KO spines. For expression analysis comparing full-
length and truncated OGT, the laser intensity varied slightly between images to account 
for differences in expression level per cell. The differences were minor and were not 
consistently lower or higher for either mutant and did not affect the interpretation of the 
experiment. While all analysis was done on raw, unmanipulated images, for image 
presentation purposes, most images shown in the figures were improved post hoc. Within 
the same experiment, all changes were done in the same way between Wt and KO 
images. The manipulations were applied in Photoshop and MS Paint and included: Levels 
and Brightness/Contrast and Filtering (‘Despeckle’ and ‘Gaussian blur’).  
 Statistical analysis. Student’s t-tests were unpaired and two-tailed. Star, ‘*’, 









CHARACTERIZATION OF THE O-
GLCNACYLATION OF PROTEIN 4.1N AND GLUA2 
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4.1 Introduction 
Several studies have reported that multiple proteins in the brain are O-GlcNAcylated. 
Those studies that identify what particular proteins contain O-GlcNAc are mostly based 
on mass spectrometry (3, 193). We have shown that O-GlcNAc transferase (OGT) is 
highly expressed in the postsynaptic density and regulates AMPA receptor expression, 
probably via a posttranscriptional mechanism (Lagerlöf et al. (2016), Science. In press, 
Lagerlöf et al. In preparation). Here we tested whether protein 4.1N, a protein that binds 
GluA1 and is critical for the cell surface expression of GluA1, or GluA1-3 are O-
GlcNAcylated.  
4.2 Results 
4.2.1 Protein 4.1N 
Protein 4.1N was immunoprecipitated from forebrain and probed for O-GlcNAc using 
Western blotting with an O-GlcNAc antibody (Fig. 4.1A). The band corresponding to 
protein 4.1N reacted against an O-GlcNAc antiobdy, and this signal could be competed 
off with 0.5M free GlcNAc. We treated neuronal cell cultures with either vehicle or 
Thiamet-G (an inhibitor to OGA). After 4 h, the O-GlcNAc signal on 4.1N was 
dramatically increased (Fig. 4.1B). Interestingly, adding NMDA to the cultures also 
appeared to increase the O-GlcNAc signal on 4.1N (but the effect did not reach 
significance, P=0.09, not shown) (Fig. 4.1C). 4.1N was then overexpressed in autologous 
cell culture, immunopreciptated and mixed with in vitro-purified OGT together with 
radiolabeled UDP-GlcNAc. After only a few days, we picked up a strong OGT-
dependent signal from 4.1N (Fig. 4.1D).  
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4.2.2 GluA1-3 
GluA1 and GluA2 were immunoprecipitated from neuronal cultures or the brain (not 
shown) and then Western blotted for O-GlcNAc. While there was a band reacting against 
the O-GlcNAc antibody laying very close to the band specific for GluA2, they did not 
exactly overlap (Fig. 4.2A). For GluA1, there were O-GlcNAc bands also in the GluA1 
immunoprecipitate but these were, in comparison to GluA2, farther away from the GluA1 
band (Fig. 4.2A). When GluA1 and GluA2 were overexpressed and pulled down from 
autologous cell culture, there was no specific signal from O-GlcNAc corresponding to 
either AMPA receptor isoform (Fig. 4.2B). However, when the C-terminal tails were 
overexpressed and pulled down in a similar way, O-GlcNAc appeared to react against the 
GluA1 and the GluA2 C-tails; the O-GlcNAc antibody also stained the tag linked to the 
C-tails used for the pull-down but to a lesser degree (Fig. 4.2C). We also overexpressed 
and mixed the C-tail pull-downs with in vitro-purified OGT and radiolabeled UDP-
GlcNAc. After months of exposure, we observed signal from GluA2, but also GluA1 to 
some extent (Fig. 4.2D). Similar result was seen with the C-tail of GluA3 (not shown). 
Next, to increase any possible O-GlcNAcylated population of GluA2, brain lysate was 
first mixed and pulled down with sWGA beads (which bind terminal GlcNAc). The 
pulled-down material was eluted with either GlcNAc or GalNAc and then 
immunoprecipitated with an antibody against GluA2 and blotted for O-GlcNAc. GluA2 
did enrich in the sWGA precipitate and O-GlcNAc signal was only observed in the 
GlcNAc-eluted GluA2 immunoprecipitate (Fig. 4.2E). In another experiment, GluA2 was 
immunoprecipitated from brain lysate and then mixed with enzymes cleaving any O-
linked or N-linked sugars before blotted for O-GlcNAc. Hydrolysis of O-linked sugars 
 101 
removed the O-GlcNAc staining from the GluA2-related band. While hydrolysis of N-
linked sugars did cause a mobility shift in GluA2, as expected from a transmembrane 
protein, it did not cause a similar shift in the O-GlcNAc band. After the mobility shift, 
there was no O-GlcNAc band detected near GluA2 (Fig. 4.2F).  
4.3 Discussion 
Here we present preliminary data validating older mass spectrometric reports that protein 
4.1N, a protein that binds GluA1 and is critical for the cell surface expression of GluA1, 
is O-GlcNAcylated (3). Our observations indicate that 4.1N may be dynamically 
modified, including by NMDA-dependent signaling. We have also characterized whether 
the AMPA receptor subunits GluA1-3 are O-GlcNAcylated. GluA1-3 appear to be 
substrates of OGT in vitro. While we reproduce a previous finding that 
immunoprecipitation of GluA2 reacts against an antibody for O-GlcNAc, our preliminary 
















Fig. 4.1. Protein 4.1N is O-GlcNAcylated. (A) Wb of immunoprecipitation of 4.1N 
form brain. (B) Wb of immunoprecipitation of 4.1N form neuronal culture after treatment 
with Thiamet-G. (C) Wb of immunoprecipitation of 4.1N form culture after treatment 
with NMDA. (D) In vitro labeling of 4.1N with radioactive O-GlcNAc. Left: Wb of 
lysate from 293 cells transfected with 4.1N or an empty plasmid. Right: 4.1N was 








Fig. 4.2. The GluA2 C-terminus may be a target of OGT in vitro. (A) Wb probing for 
O-GlcNAc on GluA1 and GluA2 immunoprecipitates from neuronal culture. (B). 293 
cells were transfected with GluA1, GluA2 or empty vector. The image is showing Wb 
probing for O-GlcNAc on immunoprecipitates. (C) 293 cells were transfected with the C-
terminus of GluA1, GluA2 or empty vector. The image is showing Wb probing for O-
GlcNAc on immunoprecipitates. (D) In vitro labeling of GluA1/2 C-termini with 
radioactive O-GlcNAc. 293 cells were transfected with the C-terminus of GluA1, GluA2 
or empty vector. The C-termini were pulled down and radiolabeled and then separated 
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using SDS-PAGE. (E) Wb of sWGA-enriched GluA2 immunoprecipitates. (F) Wb 























4.4 Materials and Methods 
Materials. Antibodies used were: O-GlcNAc (110.6, produced in-house, 1:10000), 
GluA1 (4.9D and JH4294, produced in-house, 1:10000 and 1:5000, respectively), GluA2 
(Wb; Mab, produced in-house, 1:5000, GluA3 (JH4300, produced in-house, 1:5000). All 
plasmid inserts used had been generated by standard cloning techniques previously in-
house. All animals were housed according to the Johns Hopkins University Animal Care 
and Use Committee guidelines. 
 Primary neuronal cell culture. Rat neurons were prepared from cortex according to 
standard procedures, see chapter 3. SDS-PAGE and Western blotting were done 
according to standard procedures.  
 Protein isolation, labeling and blotting. Cells were lysed in RIPA buffer (50mM 
tris, 150mM sodium chloride, 1% NP-40, 1% deoxycholate, 0.1% SDS, 1mM EDTA, 
including inhibitors for proteases, phosphatases and O-GlcNAcases). The lysates were 
mixed with the given antibody for 2-4 h and then with beads for 1-2 h and eluted with 
SDS sample buffer. N-linked sugars were cleaved using PNGase F and O-GlcNAc was 
cleaved using CpNAGj. For sWGA pull-downs, the lysate was first mixed with 
commercially available sWGA beads and eluted with free GlcNAc or GalNAc before 
immunoprecipitation with a GluA2 antibody was started. Western blotting, in vitro 
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Notes 
Most content included here is modified from work published previously, including: 
1. Lagerlöf O and Hart GW (2014). O-GlcNAcylation of Neuronal Proteins: Roles in 
Neuronal Functions and in Neurodegeneration. Book Chapter in the book 'Glycobiology of the 
nervous system'. Springer.  
5.1 Final remarks and Outlook 
Every time we think, act and feel information is passed between neurons in the brain. 
Neurons are extraordinary cells with complex morphology and a lifespan that matches the 
lifespan of the organism. The posttranslational modification O-GlcNAc, the attachment 
of -N-acetylglucosamine to serine and threonine, is expressed in all compartments of the 
neuron. By the help of only two enzymes, OGT and OGA, O-GlcNAc regulates 
thousands of proteins underlying diverse cellular processes such as gene transcription and 
signal transduction. In this dissertation, we have established a role for O-GlcNAc as a 
regulator of excitatory synaptic function and adaptive behavior. In particular, our 
observations indicate that the regulation of excitatory synapse number by OGT is an 
important pathway by which the brain controls food intake and meal size. The big 
challenge for the future will be to derive a mechanistic picture how specific O-GlcNAc 
sites affect protein function and thereby synaptic transmission. Recently, several new 
techniques have been developed that improve and simplify the detection of O-GlcNAc. 
Nevertheless, more tools such as site-specific antibodies for O-GlcNAc are needed to 
make the O-GlcNAc field more accessible to the broader neuroscience research 
community. It may appear a distant goal, but eventually the field needs efficient methods 
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enabling putting on or taking off O-GlcNAc at single and specific sites in vivo. 
Understanding the way O-GlcNAc works in the nervous system will not only afford 
fundamental principles of brain function but also provide novel targets for the treatment 
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